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CHAPTER 1: INTRODUCTION 
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SUMMARY 
This research work is related to the development of an enhanced method for the 
treatment verification of Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated 
Arc Therapy (VMAT).  Such advanced treatment techniques require accurate verification 
procedures to ensure treatments are delivered as correctly as possible.  
 
This work focused on the use of the Varian aS1000 Electronic Portal Imaging Device 
(EPID) with Dosimetry Check software-based verification system.  This EPID-based patient 
dose verification had been widely discussed and proposed as a way to achieve treatment 
delivery accuracy and patient safety, and as an ‘in vivo’ verification technique that helps to avoid 
or minimise dosimetric errors. 
 
In this work, a novel matrix-based software method to correct for backscatter effects 
from the Varian aS1000 EPID support arm has been developed.  The methodology allows a 
reliable quantification of the backscatter effect to be applied directly to the Dosimetry Check 
calibration and verification system.  This process includes the use of a clinical treatment 
planning system (Oncentra MasterPlan, Nucletron) to calculate predicted dose distribution 
within a phantom or patient, which may be compared to the dose reconstructed by Dosimetry 
Check.   
 
It has been demonstrated that the developed method can be applied to both ‘pre-
treatment’ and ‘on treatment’ portal dosimetry for IMRT Head-and-Neck.  The Gamma Index 
Method confirmed excellent validation rates of 97% (3%/3mm) and 95% (5%/3mm) for the 
‘pre-treatment’ and ‘on treatment’ approach respectively.  Pre-treatment verification of VMAT 
Head-and Neck treatment also reported excellent validation rates of 96% (3%/5mm).  In 
addition, a convenient way to use the developed methodology within Dosimetry Check 
software was also piloted and tested.  This presents an opportunity of future clinical 
implementation of the techniques developed in this investigation.    
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Chapter 1  
INTRODUCTION 
1.1 EXTERNAL BEAM RADIOTHERAPY  
External Beam Radiotherapy (EBRT) is one of the radiation delivery methods available 
to treat cancer using high-energy X-ray beams.  The beams are generated by a linear accelerator 
(linac) to transmit the X-rays through the patient’s body to kill cancer cells while sparing the 
surrounding unaffected normal tissues where possible.  Ideally, minimal radiation should pass 
through normal healthy tissue for a treatment to be successful.  Apart from utilising this 
physical treatment technique, radiotherapy’s aim also relies on the biological effects achieved 
through dose fractionation (The Royal College of Radiologists, 2008(a)). 
The rationale of dose fractionation is based on the fact that the cancerous cells and 
normal tissues possess different radiobiological properties.  After irradiation, injured normal 
tissues can be repaired in around 3-24 hours and this will give a potential therapeutic 
advantage over the tumour cells to heal from the radiation.  Over a period of treatment time, 
fractionation increases the damage to cancer cells through reoxygenation and redistribution of 
cells into radiosensitive phases of the cell cycle between fractions.  At the same time, normal 
tissue is able to repopulate and regenerate with reduction of any acute side effects.  In 
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summary, dose fractionation maximises the killing of cancer cells while limiting the damage to 
surrounding healthy tissues. 
The introduction of conformal treatment techniques (Aird, 1989a, Aird, 1989b) has 
allowed geometrical sparing of organs at risk (OAR) (Chavaudra and Bridier, 2001) and healthy 
tissues, originally using basic rectangular collimators and blocks and latterly multi-leaf 
collimators (MLCs) now present in modern radiotherapy linacs.  MLC automation takes control 
of the beam modulation to create a field of any shape required.  As a result, complex 
radiotherapy treatment techniques such as Intensity Modulated Radiation therapy (IMRT) 
(Galvin et al., 2004) and Volumetric Modulated Arc Therapy (VMAT) (Bertelsen et al., 2010, 
Alvarez-Moret et al., 2010) can be practically delivered.  These treatment techniques offer the 
capability to deliver highly conformal dose distributions to tumours with steep dose gradients 
that allow better sparing of adjacent normal tissues. 
Treatment outcome is dependent on the accuracy and reproducibility of treatment 
delivery although both dose fractionation and conformity of treatment improve tumour control 
and reduce side effects (Thames et al., 1982, Thames, 1992).  With steep dose gradients applied 
to complex radiotherapy treatments, tighter target margins have to be carefully quality assured. 
Delivery uncertainties as stated in International Commission on Radiation Units (ICRU) reports 
50 and 62 may lead to under-dosing of target and/or over-dosing of the OARs (ICRU 1994, 
1999).  Despite limiting systematic and random uncertainties, occasional treatment errors can 
sometimes occur with modern radiotherapy as it is a complex multi-step process which 
requires many inputs from different modalities and sources. 
CHAPTER 1: INTRODUCTION 
4 
 
1.2 RADIOTHERAPY ACCIDENTS AND ERRORS 
Radiotherapy errors occasionally occur, and their consequences can be significant for 
patients undergoing treatment.  According to “Towards Safer Radiotherapy”, it has been 
reported that there were 181 incidents affecting 338 patients in the UK under the Ionising 
Radiation (Medical Exposure) Regulations1 2000 (IR(ME)R 2000) from all the radiotherapy 
departments in the England, Wales and Scotland over the period of May 2000 to August 2006 
(The Royal College of Radiologists, 2008(a)).  In about 80% of the 181 cases, the patient was not 
expected to suffer any adverse clinical effects from the error.  From the incidents, 90% were 
caused by a variety of error sources which included practical aspects of the treatment design, 
preparation or delivery.  
A quarterly data summary report issued by the UK National Health Service (NHS), 
through their National Reporting and Learning System (NRLS), has identified seven main 
themes, from which radiotherapy errors are most likely to occur (National Health Service, UK, 
2017) (Figure 1.1 and Figure 1.2).    
 
 
 
                                                        
1 Requirements of Ionising Radiations from Department of Health, England with regard to exposures much greater 
than intended and diagnostic reference levels.  Available on : https://www.gov.uk/government/publications/the-
ionising-radiation-medical-exposure-regulations-2000 
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 Figure 1.2 - An analysis of the reported accuracy in radiotherapy treatment 
delivery errors (Taken from Patient Safety Data Summary Issue 8 report 
(National Health Service, UK, 2017)). 
Figure 1.1 - Reporting section taken from quarterly data summary issue 8 which  
focuses on radiotherapy related incidents (National Health Service, UK, 2017). 
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Generally, out of the 197 reviewed radiotherapy-related incidents, the vast majority of 
incidents were either coded as ‘no harm’ (77%) or ‘low harm’ (19%). The remaining four per 
cent were coded as ‘moderate harm’ (National Health Service, UK, 2017).  One of the recent 
quarterly radiotherapy Newsletters of Public Health England on radiotherapy incidents and 
errors, reported that 98.1% of events during April to July 2017 were classified as minor 
radiation incidents, near misses, or other non-conformances (Public Health England, 2017b).  In 
addition, the previous newsletter published in January 2017 noted some of the points that the 
Towards Safer Radiotherapy report stated should be considered to prevent future occurrence 
of similar errors.   
“Calculations should be independently checked by a different entitled operator using a different 
method, for example a reverse calculation (Toward Safer Radiotherapy recommendation 7 and 
11)” (Public Health England, 2017a).  
 Therefore, it is an important requirement to have an accurate system for radiotherapy 
verification to complement the existing planning and delivery systems.  Improving safety in 
radiotherapy departments has induced a broad set of key recommendations (The Royal College 
of Radiologists, 2008(a)) from many important areas, one of which is for every radiotherapy 
centre to have protocols for in vivo dosimetry (IVD) monitoring to be used at the beginning of 
the treatment course for most patients.  IVD is a direct method of measuring radiation doses to 
cancer patients receiving radiation treatment while helping in identifying possible errors in 
treatment delivery.  This intervention was also recommended by the Chief Medical Officer of 
NHS England in his Annual Report in 2006 (Donaldson, 2007).   
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1.3 THE TYPES OF RADIOTHERAPY VERIFICATION  
In order to establish whether or not the right radiation dose has been delivered to the 
right target, two measurement parameters are needed: a) geometric verification, and b) 
dosimetric verification.    
The aim of geometric verification (The Royal College of Radiologists, 2008(b)) is to 
ensure positional accuracy i.e. that the radiotherapy delivered is within the target limits set by 
the uncertainty margin defined in the treatment plan.  This is achieved by comparing spatial 
information from the delivery against what is planned.  In dosimetric verification, dose 
information from the treatment delivery, which has been recorded by a detector, is compared 
to what has been generated by the dose calculation algorithm in the treatment planning system.  
This is done to ensure that a correct dose is delivered to the patient within the accepted dose 
tolerance.  Moreover, a treatment plan for a patient undergoing radiotherapy should be 
independently checked prior to the first treatment to ensure the accuracy and validity of the 
plan throughout the treatment period.  There are several steps involved in the process of 
treatment delivery from the Computed Tomography (CT) imaging and simulation procedures 
to the volume of interest (VOI) delineation procedures, through to the verification procedures 
related to the delivery of the treatment.  Details on how the radiotherapy physics planning and 
verification process are implemented in Velindre Cancer Centre, where this work was carried 
out, will be elaborated in Chapter 2.  
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1.4 PORTAL IMAGING IN GEOMETRIC AND DOSIMETRIC VERIFICATION 
1.4.1 Development of portal imaging  
Originally and now, geometric verification of radiotherapy was done using ‘portal’ 
radiographic films on kV imaging.  While not providing information on patient dosimetry, the 
use of film made it possible to analyse positional information from the image prior to the 
delivery of the full treatment.  In addition, improved port-film systems for verification purposes 
were able to produce relatively high-quality images (Langmack and Goss, 1999, Langmack, 
2001).  Hence, portal radiographic film-based verification has been used routinely over several 
decades as an essential part of Quality Assurance (QA) in radiotherapy. 
Meanwhile, dosimetric verification in radiotherapy can be undertaken by comparing a 
point dose measurement (either inside or outside the patient) with the dose predicted at the 
equivalent point by the Treatment Planning System (TPS) (Boyer et al., 1992).  Formerly, this 
was usually done using Thermoluminescent (TLD) or conventional diode dosimeters.  
However, technology developments in portal imaging over 20 years have given rise to the use 
of more electronically based planar devices to provide real-time 2D treatment verification 
(Munro, 1995, Antonuk et al., 1998, Antonuk, 2002).  Since then, such devices have had 
widespread use in radiotherapy as part of the modern linac’s design and function.  The 
development of EPIDs for dosimetry has been reviewed by many authors (van Elmpt et al., 
2008, McCurdy et al., 2001, McCurdy and Greer, 2009, Mans et al., 2010, Mijnheer et al., 2013a).  
These authors also reviewed the strategies and approaches for the use of EPIDs in clinical dose 
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verification and current clinical experience.  Some details on the use of TLDs, diodes and EPID 
dosimeters for radiotherapy verification will be given in Chapter 2. 
1.4.2 Role of EPIDs in advanced radiotherapy verification 
The role of verification becomes particularly important with the introduction of 
complex treatment techniques such as IMRT and VMAT that use inverse planning.  This is 
because an accurate radiotherapeutic dose is required to eradicate a tumour while at the same 
time minimising the radiation exposure to healthy tissue.   
Advanced methods for treatment delivery such as IMRT and VMAT require accurate 
specification of the tumour target volume, sensitive structures (or organs at risk) and associated 
dose constraints.  There is a higher probability of errors occurring in introducing a new and 
complex technique.  This prompted several international bodies to publish QA guidelines to 
perform patient-specific treatment verification when IMRT was initially introduced into clinical 
use (Ezzell et al., 2003).  There are several EPID dosimetry verification approaches with various 
methods of dose distribution evaluation either pre-treatment or in-vivo (transit dosimetry).  
Pre-treatment evaluation essentially refers to the verification of an individual treatment plan 
before the start of the delivery.  It allows detection, and ideally rectification, of an error before 
the radiation is delivered to the patient.  For example, in Stereotactic Radiosurgery, in which 
high dose is given to the patient in a single fraction, a treatment error could be impossible to 
correct.  
Routinely devised methods to improve verification of IMRT and VMAT have been 
widely discussed for pre-treatment and transit dosimetry either at the detector plane (Ma et al., 
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2000, Leal et al., 2003, Cufflin et al., 2010) or within the patient (in-vivo) (Vinall et al., 2010, 
Sabet et al., 2012, Greer, 2013).  However, the latter does not mean that the measurement is 
taken literally inside the patient, but that the dosimetric information is retrieved via a back-
projection method to calculate the dose to the patient.  As well as having the advantages of 
providing actual treatment validity, in-vivo dosimetry QA can also detect errors in patient 
positioning, change in patient anatomy, or obstruction due to the linac table arm or immobilizer 
devices.  An analysis done by Mans et al. (2010) has reported that out of 17 serious errors, nine 
of them would not have been detected by pre-treatment verification.  This has made evident the 
importance of in vivo EPID dosimetry for all treatment plans as well as the ability of the method 
to assess the dosimetric impact of deviations that were found. 
The latest and more sophisticated method to deal with in-vivo transit dosimetry is the 
use of software and EPID-based verification instead of more conventional approaches like port 
films and diodes.  Usually, by using EPID-based verification, an independent dose calculation is 
performed and verified against the TPS; therefore, no further physical measurement is required 
on each treatment plan.  Moreover, EPID-based software verification offers significant time 
saving compared to other hardware-based verification (Siochi et al., 2013).   
Dosimetry CheckTM is an EPID-based verification software system that has been utilised 
and evaluated in several centres (Fafi et al., 2013, Reilly et al., 2013, Narayanasamy et al., 2015).  
It has provided a potentially useful and effective treatment verification tool.  Furthermore, its 
features include point dose and profile verification with gamma analysis (see detail in Chapter 
3) as well as dose volume histogram (DVH) presentation in full report form (Math Resolutions, 
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2017).  More detailed explanation on the Dosimetry Check algorithm and its features are 
included in Chapter 3. 
1.5  MOTIVATION OF THE RESEARCH 
Methods and challenges with EPID verification have been well documented over the 
past few years, especially for amorphous silicon EPIDs (Boyer et al., 1992, Cremers et al., 2004, 
Winkler et al., 2005, Parent et al., 2007, Mans et al., 2010, Pejman et al., 2010, Rowshanfarzad et 
al., 2010b, Greer, 2013).  Still, one of the main technical challenges with certain EPID imagers 
(especially the Varian aS500 and aS1000 panels currently in widespread use) is that they 
produce a non-uniform dose distribution resulting from backscatter from the linac support arm 
(Monville et al., 2014), leading potentially to systematic errors in verification measurements. 
Figure 1.3 shows the linac set-up with the EPID mounted on the linac by a support 
system beneath the imager.  The cartesian coordinates for the linac are shown in Figure 1.4.  
The backscattered radiation from the support arm contributes to a significant (>5%) non-
uniformity and asymmetry in the beam profiles along ‘in-line’ (Y) direction on the EPID image 
(Figure 1.5).  It has also been reported that the magnitude of the ‘cross-line’ (X) directional 
asymmetry was around 1%, due to some additional wiring and casing to one side of the imager 
(Cufflin, 2012).  However, for the aim of this study, attention was driven to the asymmetry 
formed in the in-line direction.  Detailed studies should be done beyond the scope of this 
research, to investigate the dependency of certain parameters contributing to the cross-line 
asymmetry. 
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Figure 1.3 - An illustration set-up of a typical modern linac with EPID mounted to the linac by a support 
arm system, i.e. “Exact” arm type for Varian Trilogy system.  Red dotted arrow-the linac primary beam, 
Green dotted arrow-direction of scattered radiation from the arm to the EPID.   
Z 
X  
Y 
Figure 1.4 - The coordinate system 
defined for a linear accelerator with cross-
line direction of the beam (X-axis), in-line 
direction of the beam (Y-axis) and 
direction perpendicular to the beam (Z-
axis) 
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EPID support arm 
Treatment couch 
Gantry 
Linac primary 
beam 
Scattered 
radiation 
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From the literature, as the ionising radiation passes through the patient, it undergoes 
interaction with tissues in the body as described in Chapter 3, Figure 3.1.  Dose which has been 
absorbed in the patient’s body is a result of the contribution of the various components of the 
radiation interaction processes such as primary dose, phantom scatter dose, contaminant 
charged particle dose, and head scatter dose.  Radiation passing through the patient’s body 
without interaction, along with an amount of scattered radiation reaches the EPID positioned 
‘downstream’ from the patient.  Section 3.2.1 discusses in detail the relevant interaction 
processes and their dependencies on energy and atomic number. 
The radiation incident on the EPID is converted to measurable signal as detailed in 
Chapter 2, section 2.1.3.  Radiation backscattered from the EPID support arm and auxiliary 
components introduce an artificial asymmetry in the EPID image as illustrated in Figure 1.3.   
The effect is known as “non-uniform backscatter” and is visible in the in-plane direction in the 
(a) (b) 
Toward  
Gantry 
Toward  
Gantry 
Figure 1.5 - An example of 10x10cm2 field size EPID image acquired with linac (LA5) shows the 
effect of non-uniform backscatter (red dotted line) shown by in-line beam profile in (b) as the beam 
cuts through the Y axis of the EPID image (black dotted line) in (a). 
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upper half of the imager panel where the arm is mounted, which provides the largest source of 
backscatter (Figure 1.5).  This effect has to be accounted for when performing dose verification. 
Hence, for this research, emphasis will be given in addressing this issue by introducing a 
novel method of reducing this backscatter effect from the EPID (Varian aS1000) arm in use 
locally.  This research aims to develop a key correction to improve the accuracy of radiotherapy 
verification (IMRT/VMAT) by evaluation of the long-standing challenge of EPID non-uniform 
backscatter, to make Dosimetry Check a reliable independent radiotherapy verification tool.   
1.6  THESIS OUTLINE  
This thesis is organised in the following way and summarised pictorially in Figure 1.6.  
Chapter 2 introduces the evolution of verification techniques used in radiotherapy and 
how their application to modern methods enhances treatment verification.  This chapter also 
includes a description of the Velindre Cancer Centre networking system, including the Picture 
Archiving and Communication System (PACS), and how medical image and radiotherapy data 
are transmitted, stored and used in the Digital Image and Communication in Medicine 
(DICOM2) format. 
Chapter 3 discusses the methods involved in radiotherapy dose calculation and includes 
a description of algorithms used in the Oncentra MasterPlan TPS used clinically in Velindre 
                                                        
2 http://dicom.nema.org/standard.html 
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Cancer Centre and the photon transport modelling algorithm in the Electron Gamma Shower 
(EGSnrc) Monte Carlo (MC) code.  This chapter also includes the deconvolution-based method 
used in the Dosimetry Check software package for dosimetric back projection, which is the core 
methodology of this research. 
Chapter 4 reports on the modelling work of the Varian 2100CD TRILOGY linac system 
(in use clinically at Velindre Cancer Centre) carried out using the BEAMnrc and DOSXYZnrc 
Monte Carlo codes which are based on the EGSnrc code system.  In addition, Oncentra dose 
calculations were verified by Monte Carlo simulation and 3-way comparison was done with 
measurements by diode and ionisation chamber. 
Chapter 5 gives details on the commissioning of the Dosimetry Check system performed 
as part of this work, including the application of a novel backscatter correction from the EPID 
arm to improve the verification accuracy for IMRT delivery techniques for pre-treatment and 
exit dosimetry. 
Chapter 6 investigates the application of the novel backscatter correction method to the 
VMAT technique for pre-treatment verification purposes. In addition, the utilisation of the 
correction method is explored in terms of benefit to clinical use by enhancing the accuracy of 
Dosimetry Check.   
Chapter 7 summarises the whole thesis and discusses the outcomes of the research.  
This chapter also identifies areas for future development. 
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Figure 1.6 - Illustration of thesis architecture.  
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Chapter 2   
RADIOTHERPY VERIFICATION 
This chapter describes how radiotherapy treatment verification is achieved using 
various portal dosimetry techniques.  It also considers advantages and limitations of such 
methods in providing the accuracy required for radiotherapy verification purposes.  In addition, 
the connectivity of hospital networks, especially in radiotherapy and physics departments such 
as those in the Velindre Cancer Centre, are discussed to provide a clear picture of how 
communication between different modalities and systems is achieved. 
2.1 EVOLUTION OF IMRT/VMAT VERIFICATION USING PORTAL 
DOSIMETRY 
2.1.1 Film-based dosimetry 
In this section, discussion is centred particularly on the role of film-based dosimetry in 
the verification of radiotherapy.  Film-based dosimetry can be divided into two categories: one 
is dosimetry based on radiographic film that is traditionally used for diagnostic purposes and 
the other is radiochromic film dosimetry that is now widely used in radiotherapy verification.  
As well as being different in their principles of operation, they are also different as regards 
certain other physics characteristics.   
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Radiographic film (Figure 2.1(a)) consists of a radiation sensitive emulsion, which is 
silver bromide, AgBr, or silver chloride, AgCl.  It is flexible and transparent.  When exposed to 
radiation, a chemical reaction takes place and some of the Br- or Cl  ¯ions liberate electrons that 
are captured by Ag+ ions to form neutral silver atoms.  This change is so small in nature that it 
cannot be detected using any devices and forms what is called a “latent” (hidden) image.   
However, silver halide crystals with a latent image are more sensitive to a developing process 
when exposed to a chemical solution (developer), and the reaction results in the formation of 
black, metallic silver.  Hence, an image is formed when this silver (Ag) is embedded in the 
emulsion on both sides of the film.  The degree of film darkening or Optical Density (OD) 
depends on the amount of silver deposited and is a function of absorbed dose as described by 
the Hurter-Driffield curve, a plot of OD (log of opacity) versus the log of exposure in the 
radiographic field (Hurter, 1890). 
Radiochromic film (Figure 2.1(b)) consists of a single or double layer of radiation 
sensitive organic microcrystal monomers, on a thin polyester base.  The crystals in the 
radiosensitive layer undergo polymerisation when exposed to radiation and cause the film 
colour to change progressively into different shades of blue (Sankar et al., 2006).  The darkness 
of the film increases with increasing absorbed dose and can be measured as OD by using a 
flatbed document scanner in transmission mode (Devic et al., 2005, Paelinck et al., 2007, Devic, 
2011).   
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Although both types of film have been used for 2D patient-specific pre-treatment QA, 
radiochromic film has many advantages over radiographic film.  One of them is that 
radiochromic films are insensitive to visible light and do not require chemical processing in a 
‘dark room’ environment.  Radiochromic film also responds to a larger dynamic range of 
megavoltage treatments (up to 40Gy for Gafchromic EBT2 film) and is suitable for pre-
treatment verification of planar dose and individual field dose maps (Tangboonduangjit et al., 
2003).   
Another major advantage of radiochromic over radiographic film is that it has a low 
energy dependency (Arjomandy et al., 2010) due to its nearly tissue equivalent radiosensitive 
layer.  A study by Moylan et al. (2013) proved the capability of Gafchromic EBT3 film to provide 
an accurate dose measurement for in vivo dosimetry for QA verification.  Mancosu et al. (2015) 
also studied Gafchromic EBT3 film for VMAT verification and demonstrated that the delivered 
dose agreed with the planned dose when a gamma agreement index of 5%/5mm was 
computed. 
 
 
 
 
. 
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Figure 2.1 - Structural diagram of (a) radiographic film, and (b) i), ii) and iii); 3 generations 
of EBT radiochromic film (Image taken from Devic et al. (2005)). 
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2.1.2 Thermo-luminescent and diode dosimeters 
For in vivo verification, especially when it involves only point dose measurements, the 
use of TLD is a standard technique.  Basically, TLD determines a dose by measuring the 
intensity of visible light emitted from a crystal in the detector when the crystal is heated post-
irradiation.  The importance of this thermo-luminescence phenomenon in radiation dosimetry 
is the fact that the amount of light emitted is proportional to the dose.  Calibration at the 
relevant dose range enables the dose received to be determined.  The two most common types 
of TLD materials are Calcium Fluoride (CaF) and Lithium Fluoride (LiF). 
In TLD, the crystals to be used for patient dosimetry are annealed or heated in an oven 
for 24 hours prior to use.  They are placed on the patient during treatment and subsequently 
read post-irradiation by a specialised TLD reader.  The reader consists of a heating element and 
photomultiplier tube.  However, while being appropriate for point dose measurement, the 
major disadvantage of TLD is that it is very time consuming because of the necessary processes 
of dosimeter preparation before and readout after the delivery of treatment.  Moreover, TLDs 
are relatively sensitive to light causing them to “fade” and decrease the signal sensitivity to 
radiation.   
An alternative technique is diode dosimetry.  Semiconductor diodes are primarily useful 
in radiation dosimetry because they are relatively small resulting in high radiation sensitivity 
per unit volume and good spatial resolution, especially for small field radiation.  Most diode 
dosimeters operate in a similar way to photodiodes (where light is absorbed by a diode and 
generates an induced current).  Some of the drawbacks of the diode are due to the fact that it is 
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an energy dependent device.  For example, in clinical treatment for a deep-seated tumour, such 
as prostate cancer, a diode is not the preferred dosimeter because the treatment requires 
higher energy (usually 10MV) compared to Head-and-Neck or breast treatment (Essers and 
Mijnheer, 1999, Mijnheer et al., 2013a).   
2.1.3 EPID dosimetry 
The EPID was first developed with the intention to replace film for positional 
verification in radiotherapy as the complexity of radiotherapy techniques increased.  This 
incentive was due to the fact that incorrect delivery of megavoltage energy beams could lead to 
serious harm to the patient’s healthy tissues and ineffective treatment to the target tumour.  In 
addition, it became increasingly important to ensure that the validity of delivery of the 
prescribed dose to the patient was within the dose constraints set by publications ICRU 62 
(ICRU, 1999) and ICRU 83 (ICRU, 2010).  Regarding positioning of patients who undergo 
treatments of several weeks’ duration, some of them lose weight during this time.  Therefore, 
their anatomy will be changed compared to that in the CT or magnetic resonance image taken 
before the treatment.   EPIDs have practically replaced portal positioning films and are used to 
obtain real-time digital images with techniques such as Image Guided Radiation Therapy 
(IGRT) (The Royal College of Radiologists, 2008(b)).  These devices have become a standard 
incorporated part of medical linear accelerators offered by major manufacturers (Parsaei et al., 
1998). 
Among the earliest generation of EPIDs was the Scanning-Liquid Ionisation Chamber 
type.   It was designed in the Netherlands Cancer Institute by van Herk and Meertens (1988) 
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and consisted of liquid-filled ionisation chambers in a 256x256 compact matrix with ~1mm 
thickness of sensitive organic liquid (iso-octane) as the medium.  The long-term stability of a 
SLIC-EPID compared to a diode is one of its advantages.  However, the relatively long read-out 
time for this device (~20ms for each row, image scan time of 5.6s) (Essers et al., 1996)  made it 
incapable of instantaneous dose measurement but suitable for integrated dose-rate 
measurement.  The measured dose-rate can be converted into absolute dose by recording a 
continuous readout of the linac monitor chamber signal during image acquisition and the 
number of MUs delivered for the measured dose image.  The dose rate dependency of the SLIC 
EPID has been discussed by several authors (Essers et al., 1996, Tateoka et al., 2006).   
  Another early type of EPID was the camera-based photon detector which consisted of a 
fluorescent phosphor-screen with a metal plate on top (x-ray converter).  The device converted 
x-rays to visible photons via the production of high-energy electrons.  These electrons escaped 
the plate into the phosphor and energy was transformed into that of visible light.  The visible 
photons were then imaged with a video camera by mirrors and a lens.  Most of the cameras 
used were based on charged couple devices.  Essentially, the photons which fell within the area 
defined by one of the pixels were converted to one or more electrons.  The amount of electronic 
charge collected was proportional to the irradiation intensity of the respective pixel.  Thus, a 
reconstructed dose was measured by the number of electrons in each pixel.  The characteristic 
and dosimetric properties of camera-based EPIDs such as dose response, stability and warm-up 
behaviour have been studied by several groups (Heijmen et al., 1995, Althof et al., 1996, 
Franken et al., 2004, 2006, Anvari et al., 2015).  One of the limitations that were identified was 
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the scatter effect for large field sizes occurring in the optical system of the EPID (Heijmen et al., 
1995, Pasma et al., 1998). 
The most common type of EPID available today is the amorphous-silicon EPID (aSi 
EPID) or ‘flat-panel’ imager.  As with all types of EPIDs, the main advantage is in providing 2D 
high-resolution (up to 0.33mm for the new Varian aS1200 EPID) digital images without the 
need for manual processing.  The EPID is particularly attractive for dose measurement due to 
the convenience of the panel being readily available as a fixed attachment to most linacs and 
requiring minimal set-up.  Most importantly, it can be used for pre-treatment as well as transit 
dosimetry verification purposes.  Figure 2.2 (a) and (b) shows an example of a SLIC and camera-
based type of EPID mounted on linacs respectively manufactured by different vendors.  In the 
remainder of this section, the discussion considers the modern amorphous-silicon (aSi) type 
EPID rather than the previous generations of this device.    
 
 
 
 
 
 
 
Figure 2.2 - Examples of the earliest versions of EPIDs which have been on the market.  
(a) LC250 PortalVision ‘SLIC’ EPID (Varian, Palo Alto, CA, USA),                                                     
(b) TheraView NT (Cablon, Leusden, The Netherlands) 
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An aSi flat panel imager consists of a copper plate, a fluorescent layer and a photodiode 
system (Figure 2.3).  The copper plate functions as a ‘converter’ to produce electrons when 
photons strike it.  At the same time, it absorbs low energy scattered radiation that reduces 
image contrast.  A layer of Gadolinium Oxysulphide (Gd2O2S:Tb) phosphor is used to convert 
incident radiation into visible light.  An array of photodiodes underneath the fluorescent layer 
absorbs this visible light and integrates the resulting charge through Thin-Film-Transistors 
(TFTs) embedded on the aSi panel.  Each TFT acts as a switch for the row-by-row read-out 
process.   
Read-out, amplification, and digitisation of the signals are controlled by the acquisition 
electronics of the panel imager (either IAS2 or IAS3 systems for Varian a-Si EPID).  Review 
articles on the aSi imager discuss its characteristics and its advantages over other detectors 
(Boyer et al., 1992, Antonuk et al., 1996, Berger et al., 2006, Parent et al., 2007, van Elmpt et al., 
2008, Greer et al., 2009).  Figure 2.4 shows the newest EPID panel, aS1200 provided by Varian 
(Varian, Palo Alto, CA, USA). 
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Figure 2.3 - The structural principle of an indirect flat panel detector, comprising a scintillator, 
an array (comprising photodiodes D, switch elements S and an active readout matrix made of 
amorphous silicon) of activation and readout electronics, (with line driver Z and a multiplexer 
amplifier M) (Soukal and Spahn, 2012).  
Figure 2.4 - i) A cut out layer of the new Varian PortalVision aS1200 consisting of the detector 
elements and also a built-in lead plate as shielding from the linac arm backscatter.             
ii) aS1200 detector panel (Taken from MyVarian Webinar (Reilly, 2016(b)). 
Metal plate, 1mm 
Copper 
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There are many aspects of the aSi EPID that can illustrate its advantages over other 
types of detectors.  For instance, the aSi EPID is a 2D detector with much finer resolution 
(0.08cm for Varian aS500 and 0.04cm for Varian aS1000) compared to other 2D array devices 
(0.13cm pixel pitch for LC250 SLIC EPID).  In addition, the cost for treatment verification is 
relatively low since there is no need to purchase additional hardware or consumable items for 
this purpose.  Most importantly, aSi-EPIDs can be used for both pre-treatment (Vinall et al., 
2010, Greer, 2013) and transit dosimetry (Boissard et al., 2009, Mans et al., 2010, Mijnheer et 
al., 2013b, Blake et al., 2014, Mijnheer et al., 2015) (at imager level or in vivo) as the panel 
imager can be positioned at any level automatically and it is very convenient to set-up for most 
Varian linacs.  
In addition, passive measurement of radiation without interfering with the treatment 
delivery is intrinsic since the panel is perpendicular to the central axis of the radiation beam and 
downstream from the patient.  More recently, following the development of EPID-based 
treatment verification techniques, centres are now becoming more inclined towards EPID-
based dosimetry using various software analysis systems (Reilly et al., 2013, Fafi et al., 2013, 
Narayanasamy et al., 2015) as part of their patient-specific QA and verification for most IMRT 
and VMAT cases.    
Although arguably becoming the detector of choice for IMRT/VMAT verification 
nowadays, EPIDs also suffer from some drawbacks such as image ghosting and lag effects.  
Image ghosting is due to trapped charge in the photodiode, which later modifies the electric 
field strength in the photodiode.  The result is an undesirable latent EPID signal when 
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subsequent frames are read out.  EPIDs have also been reported to be over-responsive to low 
energy photons (particularly below 0.5MeV) as compared to water equivalent detectors (Jaffray 
et al., 1994, McCurdy and Pistorius).  This is because of the increase in cross-section for low 
energy photoelectric interactions in the copper layer of the non-water equivalent EPID.  Next, 
optical photons generated in the EPID potentially experience “self-scattering” within the EPID 
that will contribute to the image signal (McCurdy et al., 2001).  In addition, x-ray photon scatter 
generated by the treatment beam interacting with the patient can create undesirable effects 
when these relatively low energy photons are incident on the EPID.  As for the aSi-EPID, the 
system is mounted on the linac robotic arm and this has been shown to contribute significantly 
to an additional image signal due to backscattered photons.  The backscatter signal in the EPID 
(as discussed elsewhere in this thesis) is known to be asymmetrical, field size dependent, and 
field location dependent (Rowshanfarzad et al., 2010a, Berry et al., 2010, Cufflin et al., 2010). 
Differences in acquisition mode for aSi EPIDs in linac operating systems have been 
investigated by Greer and Popescu (2003) and McCurdy and Greer (2009) for Varian linacs and 
by McDermott et al. (2004) and Winkler et al. (2005) for Elekta linacs.  For example, in ‘cine 
mode’ (a continuous rather than integrated image acquisition mode) in Varian aSi-EPIDs, it has 
been shown that a certain amount of image dose is missing from the total acquisition.  This 
results from some ‘missing images’ when acquiring the frames in cine mode.  Hence, the 
expected accuracy of the aSi-EPID’s performance for VMAT application needs investigation 
regarding the optimal methods and solutions for EPID verification.  Further explanation and 
work on the dosimetric application of cine mode acquisition will be discussed in Chapter 6.  
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2.2 DIGITAL NETWORK SYSTEMS AND ENVIRONMENT 
In many hospital installations, including Velindre Cancer Centre, the development of 
Picture Archiving and Communication System (PACS) technology involves four major 
components: (i) imaging systems such as Magnetic Resonance Imaging (MRI), X-ray imaging 
equipment and Computed Tomography (CT),  (ii) a secure network for the distribution and 
exchange of patient information, (iii) workstations for viewing, processing and interpreting 
images and data, and (iv) archives for the storage and retrieval of images and related 
documents and reports.  Along with the maturing PACS technology, it has become increasingly 
recognised that standardised data exchange is required.  Hence, the whole system should use 
the DICOM standard.  In this sub-section, the importance of PACS and a brief introduction to 
DICOM are discussed to set the scene for the later chapters.    
2.2.1 PACS system 
PACS is commonly used in healthcare technology to store data and to allow 
communication between devices, especially when dealing with equipment from different 
vendors.  To overcome the storage and communication issues, a single well-managed storage 
solution is often preferred by most centres, including Velindre Cancer Centre.  
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In Velindre Cancer Centre, the DICOM Explorer3 package from PUKKA_J4 is employed 
within Medical Physics for the storage of radiotherapy-related DICOM data for which purpose it 
is capable of centralising storage and sharing oncology data across a heterogeneous mix of 
radiotherapy modalities.  There are 8 linear accelerators currently available in Velindre Cancer 
Centre: 4 of them are Elekta Synergy linacs, 2 Varian TRUEBEAM linacs and 2 others Varian 
linacs (Clinac and Trilogy).  Within the radiotherapy network, DICOM data (Metadata5 
information) are transferred electronically via PACS between CT-simulators, treatment 
planning systems, Oncology Management Systems (Mosaiq for Elekta and Aria for Varian), as 
well as RT portal verification software - Dosimetry Check (Figure 2.5).  Other hospital 
information, such as the patient’s health data, is managed by the Welsh Cancer Network 
Information System Cymru (CaNISC).   
                                                        
3 A software for Web-based image viewing, and reporting developed by PUKKA-J 
4 A UK specialist medical technology firm which provides smart software solutions for enterprise imaging and 
reporting in healthcare, with particular experience in all medical imaging related fields  
5 DICOM metadata provide information about the image data, such as the size, dimensions, bit depth, modality used 
to create the data, and equipment settings used to capture the image 
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Figure 2.5 – Radiotherapy network within Velindre Cancer Centre. 
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CaNISC allows health professionals to access important patient clinical information.  The 
CT simulator serves a diagnostic imaging purpose for treatment planning.  The machine emits 
low energy x-ray beams to take images of the anatomy which is going to be treated by 
radiotherapy.  3D-CT virtual simulator software (ProSoma) provides tools to support clinicians' 
initial planning decisions by enhancing visualisation of the patient data set and treatment 
parameters.  Oncentra MasterPlan (Nucletron) is 3D TPS software for outlining targets and 
OARs, beam modelling, dose calculation and plan reviewing.  Oncentra MasterPlan is used for 
EBRT and brachytherapy planning while BRAINLAB iPlan is used for stereotactic radiosurgery 
and stereotactic radiotherapy.  The record and verify systems are Mosaiq and Aria from Elekta 
and Varian respectively.  These interface and record information exchange between treatment 
planning and treatment delivery system.  
Meanwhile, PACS servers and storage systems act as temporary and permanent 
repositories and enable transmission of DICOM data backwards and forwards between mixed 
manufacturer radiotherapy planning modalities.  Images are automatically routed between the 
processes and computers that perform RT services such as treatment planning and treatment 
delivery.  Details of the PACS mapping in Velindre Cancer Centre are shown in Figure 2.6.   
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Figure 2.6 – Examples of PACS mapping employed in Velindre Cancer Centre consisting of preferred and fall-back features of DICOM data transfer. 
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2.2.2 DICOM-RT 
As the DICOM standard is now widely implemented in radiology, it has been extended 
for use in various sub-specialties such as radiation therapy.  In fact, one of the first extensions 
was applied to radiation therapy and this is known as DICOM-RT.  In addition to the protocol 
used in the DICOM standard, seven DICOM-RT objects have been created, each with a well-
defined data model (Law et al., 2009): (i)  RT Image, (ii) RT Dose, (iii) RT Structure Set, (iv) RT  
Plan, (v) RT Beams Treatment Record (Figure 2.7).  The other two objects are extended from 
the RT Treatment Record, being (vi) RT Brachy Treatment Record and (vii) EBRT Treatment 
Summary Record. 
2.2.2.1 Radiotherapy DICOM objects 
Being specific to radiotherapy, information retrieval from the set of DICOM-RT objects is 
different from the radiology DICOM information model but it is an extension of the DICOM 
standard as shown in Figure 2.7.  
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(i) RT Structure – This is a set of parameters which clinically describe items of significance 
in radiation therapy such as body contours, tumour volumes (e.g. gross tumour 
volume (GTV), clinical target volume (CTV), planning target volume (PTV), organs at 
risk (OARs) and other regions of interest (ROIs)) as defined by the International 
Commission on Radiation Units and Measurements (ICRU) in the ICRU 50 and ICRU 
62 guidelines (ICRU 1994, 1999).  As a simplified example, in a case of prostate 
Figure 2.7 – Chart illustrating  5 DICOM-RT objects extending from the DICOM standard.  The other 
2 objects are extended from the RT Treatment Record (Brachy and EBRT Treatment Record). 
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cancer, the target volume is the prostate gland and any periglandular cancerous 
area.  The OARs are the urinary bladder, the rectum and the femoral heads.   
(ii) RT Plan – Treatment planning is an important process for the determination of 
appropriate radiation beams to give an optimal dose distribution (section 2.2.5).  A 
clinical treatment plan may include all the structures marked on the CT scan, beam 
positions and sizes, and the dose distribution displayed on an image.  In other 
words, the RT Plan object refers to the documented information in the treatment 
plan which is generated by the TPS.  The modules described by the RT Plan are 
prescription, tolerance table, patient set-up, fraction scheme, brachytherapy or RT 
beams used in EBRT.  
(iii) RT Dose – The dose distribution for a typical treatment plan in the TPS is usually 
represented by isodose lines given as a percentage or in dose units (Gray).  Hence, 
RT Dose contains such radiation dose data from the TPS in the form of a ‘dose 
matrix’. 
(iv) RT Image – Attributes in RT image include data from Digitally Reconstructed 
Radiographs (DRRs) generated using CT scans by a TPS, and those from images 
acquired at linear accelerators.  In contrast to ordinary CT scan images, RT Image 
data include supplemental information about the presentation of the images e.g. 
position, plane and orientation of the image and distance from radiation source to 
imaging plane.  In addition, table position, isocentre location and the MLCs or jaws 
used can be added into RT Image if necessary. 
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(v) RT Treatment Record – This can be divided into RT Beams Treatment Record and 
RT Brachy Treatment Record.  RT Beams Treatment Record includes mainly 
information from the treatment verification system gathered during the course of 
EBRT or during treatment delivery.  Examples include machine used, radiation type 
and energy, date and time of treatment, beam details and accessories, treatment 
fractions, Monitor Units (MU), calculated dose, cumulative dose, verification image 
obtained and treatment summary.  These information elements are mostly in the 
term of textual data.  For RT Brachy Treatment Record, the content is mainly 
information acquired during the course of brachytherapy along with an optional 
treatment summary. 
(vi) RT Treatment Summary Record – This is a cumulative summarisation of the 
radiation treatment, including both EBRT and Brachytherapy. 
In summary, using the DICOM-RT standard and following the PACS model makes it 
possible to integrate radiation therapy information to provide a complete radiation therapy 
patient record.  These DICOM-based RT databases can be used as a platform for sharing data 
and future research e.g. in medical informatics, outcome analysis of standardised data and what 
has become known as “Radiomics” (Gillies et al., 2015).  This type of research shall not be 
discussed any detail as it is not related to work presented in this thesis.  The relationship 
between DICOM-RT objects from treatment planning to treatment delivery is summarised and 
illustrated in Figure 2.8. 
CHAPTER 2: RADIOTHERAPY VERIFICATION 
38 
 
 
 
 
 
 
 
 
• Transfer of plan to 
prescription sheet 
(STEP 4) 
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2.2.2.2 Modality LUT of DICOM standard 
All DICOM files are typically generated from medical imaging devices such as CT and MRI 
scanners.  The values of each pixel on DICOM files are the raw values coming out from the 
scanners.  Therefore, to use or visualise these pixel values, transformations are often necessary.  
The mechanism used in these transformations is called a LUT, look up table (Pianykh, 2008). 
While the DICOM standard is full of LUTs of various kinds, among them is the most basic 
one, modality LUT.  Modality LUT is used to map stored pixel values to a meaningful physical 
unit.  For example, in a CT scan image, modality LUT is used to transform the output from the 
device to a Hounsfield Unit.  A typical modality LUT is stored in the DICOM file as a slope (0028, 
1053) and an intercept (0028. 1052) of a linear transformation or simply called the rescale 
operation (Equation 2.1). 
  
where x = the stored pixel values,  
               m = the value of Rescale slope (0028, 1053), 
                b = the value of Rescale intercept (0028, 1052), 
                y = the rescaled values, the meaningful unit. 
 
 
(Equation 2.1) 
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2.2.3 IMRT/VMAT treatment workflow 
In most radiotherapy physics departments, EBRT accounts for approximately 90% of 
the workload compared to Brachytherapy (internal radiation therapy) and therapeutic Nuclear 
Medicine.  Brachytherapy often plays a supplementary or complementary role to EBRT and can 
be used in the treatment of gynaecological and prostate cancers while therapeutic Nuclear 
Medicine has become largely independent of other forms of radiation therapy in most hospitals.  
Note that for this research, only EBRT workflow in the Velindre Cancer Centre Medical Physics 
department will be discussed. 
There are several steps involved from treatment planning to treatment delivery in 
radiation therapy workflow.  As an example,   IMRT treatment planning and delivery could be 
different from the more conventional 3D Conformal Radiotherapy (3DCFRT) in aspects like 
beam intensity modulation tools and QA processes (Nishimura and Komaki, 2015).  Hence, in 
this section, for simplification, an example of an IMRT prostate case workflow from treatment 
planning to treatment delivery is described. 
(1) Imaging and delineation  
The process starts with the localisation of the prostate tumour volume by the 
oncologist using pelvic images from a CT scanner (mostly) and/or other complementary 
modalities such as Positron Emission Tomography and Magnetic Resonance Imaging.  
Images are generated in DICOM format.  Volumes of interest like gross tumour volume 
(GTV), clinical target volume (CTV) and planning target volumes (PTV), are delineated as 
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prescribed by the International Commission on Radiation Units and Measurements (ICRU) 
(Chavaudra and Bridier, 2001, Stroom and Heijmen, 2002).   
Other important features like organs at risk (OARs) are also described.  These 
volumes are not only applicable to IMRT but also to other treatments like 3DCFRT.  The 
accuracy and quality of the volume definitions is essential in IMRT since this information is 
the basis for the creation of treatment plans by inverse planning algorithms (Ezzell et al., 
2003).  The inverse-planning algorithm will be discussed later in this thesis.   
(2) Configuration of the radiation beams  
The number of beams is configured and the treatment isocentre determined.  
Standard practice for isocentre placement varies among clinics.  In Velindre Cancer Centre, 
for most of the prostate cases, the isocentre is defined at the centre of the primary target 
(i.e. the centre of the prostate).  However, when a relatively wide target is to be treated, the 
isocentre is placed so as to minimise the number of adjacent fields needed to cover the 
entire target.  In IMRT, the width of the fields is limited by the travel of the MLCs.  The 
images are then transferred to the TPS workstation for the radiation field planning.   
Plan optimisation is done in the TPS based on the defined beams.  The use of several 
beams provides a higher degree of freedom in shaping the dose distribution, but an 
excessive number of beams could add extra treatment time.   
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(3) Treatment plan objectives  
Once the configuration has been determined, the next step is to determine doses to 
the intended treatment target and normal tissue.  Some objectives must be achieved (such 
as dose constraints in an IMRT plan) and dose analysis functions like dose volume 
histograms (DVHs) can be utilised.  Normally, the specified objectives in combination with 
suitable “consequences” lead to an acceptable approximation of what is desired, but the 
criteria vary among clinics.  Dose constraints and DVHs for IMRT will be described under 
section 2.2.3.  
(4) Optimisation 
In this phase, an optimum intensity distribution for each beam is determined and a 
weighting method used to create a dose distribution.  For example, dose at each voxel in 
the patient is calculated from a radiation ray that is passing through.  For advanced 
treatment techniques like IMRT or VMAT, there are some additional optimisation 
procedures that must be taken into account, such as determining the MLC sequence.  
Hence, MLC constraints should also be included in the optimisation process.  However, this 
process will not be discussed in detail. 
(5) Dose calculation  
For a clinical situation, a Collapsed Cone (CC) algorithm for dose calculation is used 
most of the time nowadays, compared to the previous widespread Pencil Beam (PB).  The 
PB algorithm has several disadvantages when dealing with heterogeneity in tissue density 
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(such as lung) although it provides faster dose calculation (Ahnesjo et al., 1992, Knoos et al., 
1995, Buzdar et al., 2010).  These calculation algorithms will be elaborated further in 
Chapter 3.  
In some cases, critical normal tissues often overlap with the PTV creating a potential 
conflict between target objectives and normal tissue constraints as occurs particularly in 
Head-and-Neck treatments.  The solution is to use pseudo (dummy) structures6 to help 
force the optimisation to minimize the dose to surrounding structures close to the PTV.   
(6) Treatment plan evaluation  
To evaluate a plan, DVHs are useful tools for summarising and comparing the 
treatment plans either in conformal RT or in IMRT.   
(7) Treatment delivery hardware  
The majority of modern IMRT delivery systems use MLCs.  They are small, 
individually motorised leaves that can be used to shape or modulate the intensity of the 
treatment field.  The ability of MLCs to shape fields (produce segments of IMRT fields) 
depends on several factors related to their physical design and control mechanism.  A 
common design has up to 60 opposed leaf pairs, with a width at the isocentre plane in the 
beam’s eye view (BEV) between 2mm and 10mm, depending on the manufacturer model.  
                                                        
6 Pseudo structures – A ‘dummy’ structure is often used to help in the optimisation of treatment planning.   The 
structures are not necessarily related to specific anatomic structures in the patient. 
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In ‘segmented IMRT’, “step-and-shoot” and “stop-and-shoot” methods are used, and the 
gantry does not move during irradiation. 
Another design consideration which must be taken into account is radiation leakage 
through the MLC leaves, as the cross-sectional shape of the MLCs is very complex.  The 
leaves must incorporate beam divergence in the direction perpendicular to their travel and 
adjacent MLCs must overlap to minimise radiation transmission between them.  This effect 
is called tongue-and-groove and has been discussed in detail elsewhere (Wang et al., 1996, 
Jonathan and Peter, 1998, Salari et al., 2011).  As in VMAT treatment delivery, leaf 
sequencing is crucial because as the MLCs move, the gantry is also rotating.  Since VMAT is 
delivered in one or more dynamically modulated arcs, the rate of rotation of the gantry and 
the linac dose rate can be modulated during treatment to give the required delivered dose 
for each gantry angle (Otto, 2008, Bedford, 2009, Bzdusek et al., 2009).  The leaf 
sequencing algorithm involved in VMAT delivery first converts the optimised intensity 
distribution into separate values of gantry spacing (usually termed control points).  By 
shifting MLC leaves, all control points are processed to comply with machine motion 
constraints of the treatment units (such as maximum leaf speed, valid dose rates and 
treatment delivery time) (Nucletron, 2008a).  
In summary, the more complex the treatment, the greater is the number of optimization 
considerations that have to be taken into account in parallel with the design limitations of the 
MLCs.  However, a productive and co-operative multidisciplinary team in the radiotherapy 
department including treatment planner, medical physicist, dosimetrist and radiographers, 
should ensure the quality and success of treatment delivery to the patient with the correct 
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prescribed dose.  In order to achieve this, a specific quality assurance process must be applied 
to accommodate the needs of treatment accuracy and precision (van Elmpt et al., 2009, Klein et 
al., 2009, Bakhtiari et al., 2011, El-Maraghy et al., 2014). 
2.2.4 Record and Verify systems  
Record and Verify (R&V) systems were originally developed to reduce the risk of 
treatment errors.  Parameters required during the treatment course such as skin markings and 
image verification were obtained through the treatment planning process either from the 
simulator or TPS.  Some early R&V systems were attached to individual treatment machines 
and designed to capture treatment parameters (such as collimator opening, gantry and 
collimator angle or presence of wedge filters) and compare them against the intended 
parameters either derived from the TPS or manually entered (International Atomic Energy 
Agency, IAEA, 2017).  However, over time, the R&V system was no longer exclusively used as 
the consistency check between prescription and actual set-up, but rather to provide effective 
control for the treatment machine while giving access to complicated treatment techniques that 
would not be feasible without such a system (Fraass, 2008). 
In fact, the R&V system has evolved into a component of a wider and more complete 
radiotherapy and oncology information management system that interconnects with the 
imaging systems, treatment planning computers and treatment delivery systems.  Today’s R&V 
systems serve not simply to record and verify the treatment set-up, but to function as an 
integral link in planning, delivery and record-keeping processes such as scheduling capabilities, 
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clinical assessment tools, image storage capabilities, dose alert functionality and other functions 
(Baiotto et al., 2009). 
As mentioned previously, Velindre Cancer Centre is a dual vendor centre and so two 
types of R&V system are used in parallel as platforms in the Oncology Management System 
(OMS) (Figure 2.9). 
 
 
 
 
 
 
CHAPTER 2: RADIOTHERAPY VERIFICATION 
47 
 
 
 
  
  
 
 
 
 
 
Figure 2.9 - Illustration of typical data exchanges between the R&V system and other pieces of equipment in the Velindre Cancer 
Centre radiotherapy department.  DRR - Digitally Reconstructed Radiograph. 
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2.2.5 Treatment Planning System  
The International Commission on Radiation Units and Measurements (ICRU) produced 
guidelines on the use of computers in treatment planning and subsequently produced a report 
on prescribing, recording and reporting procedures in EBRT (ICRU 1994, 1999, 2010).  
Nowadays, radiotherapy planning is almost exclusively performed using computer-based 
treatment planning systems.  Advances in patient imaging and radiotherapy delivery 
techniques have driven the development of more sophisticated dose calculation algorithms 
which will be discussed in in Chapter 3.  
Inverse treatment planning involving IMRT has been discussed in section 2.2.3 along 
with treatment delivery.  In this section, the discussion relates to the tools and features available 
in a Velindre Cancer Centre planning system such as Oncentra MasterPlan.     
TPSs have evolved greatly in the use of graphic capabilities for the development of more 
powerful 3D visualisation and treatment planning techniques in clinically useful timescales.  
Moreover, these have additional tools and features to accommodate planning and dose 
optimisation for every case.  The features include:  
(i) Contouring tools - for accurate VOI delineation such as those for OARs. 
(ii) Beam modelling – to enable BEV display of the field where the observer’s viewing 
point is at the radiation source and the image shows the plane of the internal patient 
contours (perpendicular to the beam central axis).  Plan field sizes and locations can be 
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adjusted manually by a user-specified margin or graphically on screen with the help of 
MLCs to shape the beam according to the shape of the tumour. 
(iii) Dose calculation – usually dose is computed within a 2-5mm range in grid spacing.  If 
the matrix size is reduced, it will take a longer time for the system to compute the dose.  
Based on ICRU report 50, the position of the maximum dose within the plan and the 
reference point are specified (ICRU, 1994).  Normalisation should be done either such 
that the ICRU reference point lies on the 100% isodose, or such that the mean (or 
median) target dose is equal to the 100% isodose value.    
(iv) Evaluation tools – to allow fast assessment of dose distributions in order to determine 
whether the tolerances for the target and critical structures have been achieved.  A key 
method of analysing the 3D dose distribution in all modern treatment planning systems 
is the DVH, with cumulative DVH mostly commonly used.  DVHs are used to determine 
the percentage of that volume receiving a dose above and below the required 
tolerances.  Higher values of the target dose below the prescription dose and a sharper 
fall-off of the DVH indicate an improved dose distribution.  In contrast, desirable dose 
distributions for critical OARs are represented by lower values of dose.  An example of a 
particular DVH assessment consisting of several PTVs, CTVs and OARs is shown in 
Figure 2.10. 
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Other essential tools that are available include (v) the Export feature and (vi) the 
Specific type of treatment planning modality, such as forward and inverse IMRT planning, 
electron beam planning, stereotactic radiosurgery planning, and brachytherapy planning.     
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Figure 2.10 – A screenshot of a DVH analysis of several PTVs, CTVs and OARs (example on a patient’s 
DVH evaluation done by using Velindre Cancer Centre Oncenra MasterPlan TPS). 
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Chapter 3  
DOSE CALCULATION ALGORITHMS IN ADVANCED RADIOTHERAPY 
This chapter considers the various dose calculation algorithms that were involved 
during this research.  These include the ‘gold standard’ Monte Carlo method for tracking 
particle histories, algorithms used in the TPS and the dose reconstruction algorithm employed 
in the Dosimetry Check software.  The ‘RTGrid’ high throughput computing system available to 
the Velindre Cancer Centre is also highlighted as a facility for timely Monte Carlo simulations.      
3.1 CONVOLUTION-BASED METHODS 
3.1.1 Energy fluence of a photon beam 
The object of radiotherapy has never deviated far from its primary goal to deliver 
accurately a dose considered sufficient to achieve local control of malignant disease whilst 
minimising the occurrence and severity of normal healthy tissue complications.  Since the 
publication and widespread adoption of the ICRU 50 and 62 reports on volume definitions 
(ICRU 1994, 1999), and the development of prescribing, recording and reporting for photon 
beam therapy, considerable efforts have been made to improve treatment accuracy, with 
uncertainties in the final delivered dose to the patient of ≤5%.  A major contribution in 
achieving this goal has come about as the result of improvements in the treatment planning 
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aspect of external beam therapy (Knoos et al., 2006).  At present, for most non-stereotactic 
cases at Velindre Cancer Centre, dose distributions are principally determined by Nucletron’s 
OncentraTM MasterPlan (OMP) TPS, with calculation available in two ‘kernel-based’ algorithms.  
One algorithm is known as Pencil Beam (PB) and the other is called Collapsed-Cone (CC). 
OMP simulates the geometry and physics of the beam set-up and patient anatomy for 
3D radiotherapy treatment planning in order to represent the actual situation.  Before the 
energy is absorbed as dose, there is a cascade of interactions which occurs in the treatment 
machine itself, prior to interactions within the patient or phantom (Figure 3.1).  Within OMP a 
calculation dose grid is used to represent the embedded radiation ray path, and this directly 
mimics the transport of primary photon beams.  Secondary photon components are also 
generated following irradiation of the treatment head element.  The transport and dose 
deposition of secondary particles is implicitly considered through the use of energy deposition 
kernels i.e. ‘pencil’ kernel for the PB algorithm (Ahnesjo et al., 1992, Zhang et al., 2014), and 
‘point’ kernel for the CC algorithm (Ahnesjo, 1989).  The term energy deposition kernel is used 
generically to describe the dose response to an incident elementary radiation beam in water 
while the elementary radiation geometry can be of various different types.      
Absolute dose per treatment machine MU7 is calculated relative to the dose at reference 
or calibration conditions.  The recommended standard set-up for treatment linacs with a 
source-axis distance (SAD) of 100cm is to have the isocentre at 10cm depth and a source-
                                                        
7 Monitor Unit, MU - a measure of machine output from a clinical accelerator for radiation therapy such as a linear 
accelerator or an orthovoltage unit. 
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surface distance (SSD) of 90cm along the central axis of an open 10x10cm2 field.  However, it is 
possible to use other appropriate depth and SSD values, provided that the depth is well beyond 
the position of maximum dose, dmax8 in the water phantom. 
In general, the dose (D) calculated by a TPS at any point in a water phantom or a patient 
is based on an ‘energy fluence’9 formalism, which is associated with machine-related beam 
quantities.  This formalism (Equation 3.1) generally includes the treatment head scatter fluence, 
which is a consequence of radiation interactions and transport through various linac 
component modules such as flattening filter, collimators (X and Y jaws, MLCs), modulating 
filters (wedges, compensators), and monitor ion chamber (Figure 3.2) (Khan and Gibbons, 
2014).  However, this formalism is dependent on whether a SSD or SAD set-up is applied, and 
its discussion is limited given the scope of this thesis.    
 
 
 
 
 
                                                        
8 dmax – depth in water where the deposited dose is at its maximum 
9 Energy fluence - describes the energy flow in a photon beam and is defined as the amount of energy dE crossing a 
unit area dA.  Its usual unit is MeV/cm2. 
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TFOAFDDFISqOFOMUD =    
 
where: 
MU = monitor unit setting for given conditions 
O = calibrated output (cGy/MU) for standard conditions 
OF = output (scatter, phantom/patient, total) factor(s): SC, SP, ST  according to which approach 
is applicable) 
ISq = inverse-square correction (if needed) depending on calibration conditions and 
treatment conditions. 
DDF = depth-dose factors (Percentage Depth Dose (PDD), Tissue Maximum Ratio (TMR), 
Tissue Phantom Ratio (TPR), Tissue Air Ratio (TAR) according to which approach is 
applicable)  
OAF = off-axis factors, open and wedge 
TF = transmission factors-attenuation 
 
 
 
(Equation 3.1) 
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Figure 3.1 - Interaction history of all dose categories commonly associated with TPS and referred to in dose calculation: 
primary dose, phantom scatter dose, contaminant charged particle dose, and head scatter dose (Image extracted and 
reproduced from Ahnesjo and Aspradakis, 1999). 
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3.1.2 Dose calculation using kernel models in OMP  
Within OMP the patient tissue distribution is represented by a 3D density matrix, and 
the properties of each voxel are either derived from pixel values in a CT image or from user-
specified values of mass or electron density.  Dose per unit incident energy fluence is calculated 
by the algorithm (PB or CC) for a given beam and patient set-up, characteristic of the beam and 
the patient anatomy.  In some publications, PB kernels are regarded as a “pre-convolution” of 
point kernels, thus their employment results in significant gains in computation time compared 
with point kernel-based approaches (Ahnesjo et al., 1992, Hong et al., 1996, Zhang et al., 2014).  
The PB algorithm is also known as a ‘type a’ algorithm (Knoos et al., 2006).  In contrast CC, 
Figure 3.2 - Collimating and modulating devices in the beam path (Image taken 
from Nucletron (2008b)).  Red dotted arrow shows the direction of the primary 
beam 
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which is a full 3D superposition or convolution method based on point kernels (Ahnesjo, 1989, 
Buzdar et al., 2010) is known as a ‘type b’ algorithm (Knoos et al., 2006).  These descriptions are 
elaborated further below. 
3.1.2.1 Pencil Beam algorithm  
PB models were introduced to provide a more accurate and suitable method to use in 
the dosimetry of conformal radiotherapy in situations that did not involve much tissue 
heterogeneity.  The model assumes that when any collimated photon beam is incident on a 
target, the beam is actually an accumulation of lots of smaller and narrower “pencil beams”.  
Each of these pencil beams has its own central axis along which it deposits some dose.   
The dose deposition patterns, however, will vary with the intensity and energy 
spectrum of the beam that is hitting the target.  For instance, taking an IMRT case as an example 
where the linac beam profile is non-uniform and modulated, the weighting and arrangement of 
the pencil beams is adjusted appropriately.  In practice, the primary photon intensity at the 
entry point on the patient and electron contamination are included.  The total incident energy of 
a pencil beam is referred to as the primary dose and the head scatter dose. 
When a single pencil beam is incident on the surface of the patient, typically a teardrop-
shaped dose distribution (Figure 3.3) results from the process of scattering and absorption of 
the primary and secondary electrons.  In principle, one might produce and use an extremely 
small collimator and detector to determine the kernel dose distribution in water 
experimentally, but practically, the more common approach is to use Monte Carlo simulations 
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to calculate the dose distribution from a pencil beam in water (Ahnesjo and Aspradakis, 1999).  
These simulations also allow us to generate dose kernels for different photon energy spectra 
very easily.  In summary, the energy deposited in a medium for PB algorithm is obtained in the 
following manner:  
(i) the irradiation geometry is firstly represented as a 3-D matrix of voxels (based on the CT 
density matrix) 
(ii) the centre of each pixel on the irradiated surface is assigned as the origin of a pencil 
kernel and all photons incident on a pixel are assumed to be concentrated at this point 
(iii) the primary fluence at each point on the surface is convolved for the entire field  
(iv) all dose contributions at each location in the 3-D matrix are integrated to calculate the 
total dose  
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However, there are some limitations to the accuracy of the pencil beam kernel model.  In 
the literature (Hong et al., 1996, Buzdar et al., 2010, Zhang et al., 2014), it has been pointed out 
that PB convolution is prone to inaccuracy in certain inhomogeneous tissue situations, 
especially in lung.  Its inability to model electron transport in close proximity to tissue 
boundaries is the main limitation of PB kernel methods (Knoos et al., 2006, Aspradakis et al., 
2003).  In other words, the PB algorithm is unable to model accurately the transport of electron 
across tissues of different density (relative to water) in the patient, as in the case of lung.   
Furthermore, PB kernels are most likely to be lacking accuracy in calculating backscatter 
and lateral scatter (as is the case in most clinical situations) where there are invariably 
inhomogeneities and/or missing tissues, thus resulting in inaccuracies in the clinical result.  
Figure 3.3 describes the pencil beam kernel algorithm in detail. 
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Figure 3.3 - (a) A single pencil beam kernel , (b) An example of a 2D fluence dose distribution 
using the pencil beam model , (c) An actual situation showing the limitation of the pencil 
beam kernel in underestimating dose at the calculation point because of the lack of 
backscatter and side-scatter (Radiology Imaging, 2017). 
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 The pencil kernel method within OMP calculates dose within the patient using 1D 
convolution.  A measured depth dose is used to derive an effective spectrum during a beam 
characterisation process. A poly-energetic pencil kernel is then derived by superposing mono-
energetic pencil kernels.  Mathematically, at each depth z, the poly-energetic pencil kernel 
(which is defined as dose deposited at point p where ρ is the electron density at p) is 
parameterised as a sum of two exponentials over the radius r in Equation 3.2 below (Ahnesjo et 
al., 1992, Ahnesjo and Aspradakis, 1999). 
 
   
where Az, az, Bz and bz are depth-dependent parameters determined by least square fitting.  In 
normal conditions, the primary dose is limited to a range within the small region surrounding 
the pencil beam axis, while the scatter dose is spread over larger region as secondary photons 
may travel longer distances before the next interaction.  So, az > bz interprets the two terms as 
primary dose and phantom scatter dose respectively.  By making this separation, the calculation 
improves the heterogeneity correction (Nucletron, 2008a).   
 
 
 
 
(Equation 3.2) 
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3.1.2.2 Collapsed Cone algorithm  
The Collapsed Cone (CC) algorithm is an approximation to a point kernel model  that 
describes the deposition of the energy from a photon interaction site as a function of direction 
and distance (Ahnesjo, 1989).  Each of the point kernels is divided in 3D into a number of 
variable solid angular bins or cones.  Figure 3.4 (a) shows the approximation that all energy 
released from primary photons travelling in any direction within the cone is rectilinearly 
transported and deposited onto the axis.  Hence, in energy deposition terms the cone is 
‘collapsed’ onto the axis.   
Figure 3.4 (b) shows the consequences of the collapsed cone approximation in 
transporting the energy along a discrete axis.  The energy that should be deposited in voxel B’ 
from interactions at the vertex of the lower cone is deposited in voxel B and vice versa (Ahnesjo, 
1989).  The displacement between voxel B’ and B is increased with distance, but the first scatter 
fraction decreases with increasing distance.  This allows the total energy deposited to be 
conserved.  Most energy is deposited close to where it is released, making displacement errors 
less important.   
In the standard implementation of the CC algorithm in OMP, 106 different cones are 
used: 60 lie in the forward direction, 40 in the lateral direction and 6 in the backward direction 
from the kernel origin (Figure 3.5).    
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Figure 3.4 - (a) Collapsed angular cones within the central axis with energy rectilinearly 
transported and deposited on the axis. (b) Consequences of the CC approximation to 
transport energy along a discrete axis.  The energy that should be deposited in voxel B’ from 
interactions at the vertex of the lower cone is deposited in voxel B and vice versa (Image 
taken from (Ahnesjo, 1989)).    
Figure 3.5 - Set of directions of the point 
kernel with angular binnings.  There are 
106 different directions used in the 
Oncentra standard configuration. 
(Image taken from Oncentra –Physics 
and Algorithms manual version 4.3). 
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Convolution based point kernel models use the fact that in homogeneous media the 
point is independent of location.  Total energy released in the medium (TERMA) is calculated by 
this point kernel which enables dose for a clinical beam to be computed.  For each direction the 
kernel is parameterised as: 
( )
2r
Ae
rh
ar−
=  
where r indicates the distance to the interaction point, a is the range of energy transport from 
the interaction point and A/a equals the fraction of energy transported in the given direction 
per unit solid angle.  Two sets of point kernels are used in OMP, one to obtain primary dose by 
energy released from the primary photons and the other to obtain phantom scattered dose by 
energy released from scattered photons.  These two main parameters are deposited as the total 
absorbed dose.  Hence, Equation 3.3 is modified to give Equation 3.4 for the CC algorithm in 
order to speed up computational time. 
 
 
For the calculation of dose in heterogeneous media, any modulation in the ‘primary’ 
part of the kernel (for example changes in relative mass stopping power of secondary 
(Equation 3.3) 
(Equation 3.4) 
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electrons10) and in the ‘scatter’ part (for example changes in relative mass attenuation 
coefficient11 of scattered photons) are both approximated with variations in electron density 
between media.  So, this model is more capable of dealing with electron transport at tissue 
boundaries (Aspradakis et al., 2003) in heterogeneous media compared to the PB algorithm.    
Despite the advantage of CC relative to PB, CC has its own limitations.  One known 
limitation is the extension of the penumbral region (Knoos et al., 1995, Aspradakis et al., 2003, 
Knoos et al., 2006) in the fluence matrix.  However, this can be improved by ensuring that the 
dose matrix and patient density matrix are of close or equal dimensions prior to calculation.   
For the optimisation work using the TPS discussed hereafter in this research, 
calculations involved the PB algorithm unless stated otherwise.  This is because most of the 
verification and proof of concept work in this research was dose using a homogeneous water 
phantom, rather than the ‘real’ patient, and PB is the algorithm currently deployed in VCC as 
described in Section 3.3 below.     
                                                        
10 Mass stopping power of secondary electron - the energy released by the charged particles (secondary electrons 
and possibly positrons) per unit areal density.  
11 Mass attenuation coefficient - fractional number of photons lost (or fractional decrease in intensity) per unit areal 
density (which units in gcm-2) in the direction of the radiation travelled. 
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3.2 MONTE CARLO DOSE CALCULATION ALGORITHM 
3.2.1 Photon transport modelling using EGSnrc package 
To understand the fundamentals of radiotherapy, photon and electron radiation 
interaction with matter is an essential aspect which needs to be covered.  For example, in the 
kilovoltage energy range, 5–140keV (Ali and Rogers, 2008), the photoelectric effect 
predominates since the probability of interaction decreases strongly as photon energy 
increases (~E-3=~hv-3).  This is independent of the fact that photoelectric absorption cross-
section, σph also increases as the atomic number, Z of the material subject to radiation (~Z4). 
 
 
In intermediate energies (ranging from 100keV to 10MeV), incoherent Compton 
scattering events take place, which depend on electron density, which is proportional to Z/A 
(where A is the mass number).  For most elements, Z/A is about 0.5; the main exception is for 
hydrogen, for which Z/A is 1.  At some high energies (above 5MeV), pair production dominates.  
Electrons lose their energy via collision and radiation as they traverse across matter.  Therefore, 
tracking the passage of radiation is crucial and requires a transport analysis which accounts for 
electron trajectory through any geometry. 
MC codes provide numerical and statistical methods to model radiation transport 
(involving entities such as photons, electrons, neutrons, protons, charged nuclei, atoms, and 
molecules) in the field of Medical Physics (Seco and Verhaegen, 2013) as well as other 
 
(Equation 3.5) 
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disciplines.  MC offers a reliable radiation transport algorithm, which was widely discussed in 
the literature by medical physics practitioners and researchers in the later decades of the 20th 
century. Since then, it has been intensively used for research and development in medical 
applications (Rogers, 2006).  Chetty et al. (2007) have also described MC as follows. 
“As a technique for calculating dose in a patient, the underlying physical basis is much 
simpler in concept than analytic algorithms because the MC method consists of a straightforward 
simulation of reality and does not involve complex approximations nor models of dose deposition, 
but only a knowledge of the physics of the various interactions which have been well understood 
for over 50 years in most cases”. 
One of the most widely used MC codes at present, the EGSnrc package, was developed 
from the EGS4 (Electron Gamma Shower version 4) code (Nelson et al., 1985) by several 
authors at the Stanford Linear Accelerator Centre and National Research  Council of Canada in 
the 1980s and 1990s.  Subsequently, work by researchers such as Kawrakow (2000) and 
Kawrakow and Rogers (2013) demonstrated several improvements in the EGSnrc package 
compared to the earlier EGS4 version.  This project uses the BEAMnrc package (Rogers et al., 
2011), upgraded from the original BEAM user code (Rogers et al., 1995) for linac simulation and 
associated with the DOSXYZnrc code for dose distribution calculation within a rectilinear 
matrix.  BEAMnrc and DOSXYZnrc are part of EGSnrc.  A powerful facility in BEAMnrc allows for 
user input and easy modelling of a linear accelerator to incorporate the basic elements and 
component modules found in a real linac head (like jaws, flattening filter, secondary collimators, 
MLCs).  Therefore it is considered to be the ‘gold standard’ for photon-electron MC simulation in 
radiotherapy applications (Hasenbalg et al., 2008).   
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Usually a “phase-space” file (which fully characterises the incident beam) is used to 
represent the input to DOSXYZnrc simulations in a phantom or patient, or subsequently to be 
fed into further BEAMnrc simulations.  This file records information regarding all the particle 
types, energies and directions when crossing the relevant scoring planes.  However, there are 
practical limits to the number of particles that can be stored in a phase-space file.  For instance, 
a file storing ZLAST (the last simulated component module) would require about 69 Gigabytes 
for 231  particles (Rogers et al., 2011).   
Due to potential storage issues, an option to use a full BEAMnrc simulation of a 
treatment head as a particle source for DOSXYZnrc simulations has been made available, with 
the advantage of by-passing the intermediate phase-space data.    However, to generate a full 
linac simulation to represent each source particle requires extra computational time and this 
results in reduced temporal efficiency.  A direct comparison of efficiency between phase space 
sources and full BEAMnrc simulation sources has been made by Kawrakow and Walters 
(2006).  They reported that full BEAMnrc simulation improves efficiency (through reducing 
time) by up to a factor of about 5 for fields defined using photon jaws, and up to a factor of 6.5 
for secondary collimation with a MLC, compared with phase-space file sources.  This was 
achieved primarily by the efficient use of Variance Reduction Techniques (VRTs) such as 
photon splitting in DOSXYZnrc and directional bremsstrahlung splitting, DBS within BEAMnrc, 
rather than just particle recycling in the phase-space file.  These techniques will be explained in 
more detail in Chapter 4.    
Monte Carlo photon transport relies on accurate interaction cross-section datasets for 
the simulation.  Material compositions and densities are based on the data that has been set out 
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in ICRU report 37 (ICRU 1984).  In the EGSnrc package, there are 2 data sets available: ICRU 521 
and ICRU 700, which correspond to a threshold kinetic energy for secondary electron 
production of 10keV and 189keV respectively (relative to the 511keV electron rest energy).   
Electron cut off (ECUT) is used in conjunction with photon cut off (PCUT) to increase the 
calculation speed in MC simulations.  This means that if the particle energy falls below the 
relevant cut off, the particle trajectory is terminated, and its energy is deposited in the current 
region.  This reflects the main reason for using different cross-sectional data, as different 
secondary electron cut-off energy may be used to increase the accuracy or the speed of 
calculation.  In addition, electron range rejection involves terminating electron tracks with the 
residual range and this keeps them from getting to the scoring plane.   
As an example of ICRU cross-section dataset selection, if ICRU 521 is used as ECUT 
(which will be explained in later sections), the kinetic energy cut off is 521keV - 511keV = 
10keV.  Similarly, when ICRU 700 is selected as ECUT, the kinetic energy cut off is 700keV – 
511keV = 189keV.  Hence, as soon as the total energy is below ECUT, the particle history is 
terminated, and energy is deposited locally.   However, the cut-off energy of photons (PCUT) is 
the same (10keV) for both data sets. 
For the transport of secondary electrons, the situation is far more complicated than for 
the transport of photons, since electrons undergo large numbers of collisions during the 
slowing down process.  To accommodate these, MC codes use ‘condensed history’ techniques 
(Kawrakow and Bielajew, 1998) to incorporate a large number of these electron interactions 
into a single step.  If the step is short, it increases the accuracy of the simulation.  ESTEPE and 
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SMAX are parameters introduced into EGSnrc, which represent the maximum fractional 
electron energy loss per electron step and the maximum electron step allowed respectively.   
3.2.2 Distributed computing system in Velindre Cancer Centre 
Most of the validation work for the linac modelled in this thesis was undertaken using 
the Cardiff University and Velindre Cancer Centre ‘RTGrid’ web-based service (version 2.0) 
(Downes et al., 2009) powered by GridSphere12, although some of the basic simulations were 
done by using a single processor for the purpose of basic understanding of the EGSnrc MC 
system.  The RTGrid system is used as a platform to provide high throughput simulations, 
together with appropriate variance reduction techniques, to reduce the calculation time for 
treatment plan verification to clinically useful levels.   
RTGrid is based on a graphical user interface using a service-oriented architecture 
similar to that discussed by Yaikhom et al. (2008).  Any MC simulation jobs sent to the RTGrid 
use a simulation template known as the ‘Profile’.  This ‘Profile’ contains simulation data 
including executable scripts to be run at a specific phase when the simulation takes place.  The 
running of the simulation is then controlled by the ‘experiment manager’ that interacts with the 
RTGrid database and changes the simulation status depending on whether the simulation is 
‘Pending’, ‘Running’ or ‘Completed’ (Figure 3.6).   
                                                        
12 GridSphere – US based software development company responsible for designing and developing of high range of 
software solutions.  
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The user can leave the job running overnight and upon completion of the job, the 
simulation output files are generated from the collated distributed machines.  Currently, the 
deployment of distributed computing resources in Velindre Cancer Centre is based on a batch 
queuing system which utilises a Condor architecture13  based on local machines which mainly 
operate with INTEL X86_64 AMD processors. 
 
 
 
 
 
 
 
 
 
 
 
                                                        
13 Condor architecture – a batch scheduling system which provides a job queueing mechanism, scheduling policy, 
priority scheme, and resource monitoring.  Users submit their serial or parallel jobs to Condor, Condor places them 
into a queue, chooses when and where to run the jobs based upon a policy, carefully monitors their progress, and 
ultimately informs the user upon completion. 
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3.3 A DECONVOLUTION-BASED METHOD 
3.3.1 Dose calculation algorithm in “Dosimetry Check” 
The Dosimetry Check system developed by Math ResolutionsTM is an alternative to 
direct 3D IMRT and VMAT dose verification.  It is a software-based verification tool that may be 
used in conjunction with an EPID or other image acquisition array to verify dose, Map Check 
Figure 3.6 - A screenshot image of the RTGrid Portal showing the status of a particular simulation job.  All 
20 distributed machines are in 100% ‘Running’ mode but not yet completed. 
CHAPTER 3: DOSE CALCULATION ALGORITHMS IN ADVANCED RADIOHTERAPY 
74 
 
diode array, Ion Chamber array and other devices.   It is quite widely used as a system of 
dosimetric verification, which compares the planar dose reconstructed from the relevant 
detector arrays with the dose originally calculated by the TPS.  For example, by using an EPID 
panel as detector array, Dosimetry Check reconstructs and recalculates the fluence distribution 
algorithmically.  It uses EPID images acquired during treatment or before treatment for transit 
dosimetry or pre-treatment dosimetry respectively.  There are two dose calculation algorithms 
that can be used in Dosimetry Check, these being the PB and CC algorithms.  The CC version did 
not obtain a CE mark until December 2017 and hence was unavailable for clinical use at the 
time of writing.  The system uses an in-air fluence map calculated from data recorded by the 
portal imager to reconstruct a 3D dose distribution on the planning CT dataset.  The delivered 
dose calculated by Dosimetry Check is then compared against the original patient treatment 
plan.  A detailed description of the dose reconstruction method employed in the Dosimetry 
Check software is given in Chapter 5.       
For the work described within this thesis, a Varian ‘Trilogy’ linac was used with an 
‘aS1000’ EPID mounted on an ‘Exact’ arm (Varian Medical System, Palo Alto, CA, USA).  This 
machine has been clinically commissioned for Dosimetry Check in Velindre Cancer Centre 
although, to date, it has been verified with the PB kernel only.  Thus, only the Dosimetry Check 
PB algorithm will be discussed hereafter in this section.  More details of the CC kernel algorithm 
are available in the Dosimetry Check manual14.   
                                                        
14 www.mathresolutions.com/dcman.d/dcalgor.htm#_Toc451433041 
CHAPTER 3: DOSE CALCULATION ALGORITHMS IN ADVANCED RADIOHTERAPY 
75 
 
Generation of the kernel is done by the Dosimetry Check UK distributor, OSL15, with 
input (in the form of relevant acquired data) from clinics.  Briefly, the PB algorithm dose kernel 
is directly computed from measured percentage depth dose data obtained from the clinics 
(Velindre Cancer Centre for example) and Monte Carlo generated pencil kernels.   
There is a specific program within the Dosimetry Check system which computes the 
pencil kernel from measured data.  The program first calculates mono-energetic point spread 
functions using MC and then uses these functions to compute mono-energetic pencil beam 
kernels.  Next, central axis data at different field sizes is used to generate a spectrum of 
measured depth dose.  These spectra and kernels are then used to compute the dose.  The 
process of kernel generation is done by the manufacturer and a detailed description is given in 
the manual.  Following that, the commissioning process is completed by the clinic. 
In the analysis of IMRT and VMAT images, Dosimetry Check also uses the so-called 
‘gamma method’.  This is a vector calculation method developed by Low et al. (1998).  The 
gamma method is a way to compare two dose distributions by taking dose difference and 
spatial displacement between two analysis points to provide an index of comparison.   For 
example, an analysis point may be separated by a large spatial displacement from the reference 
point, but by a small dose difference such as occurs in a low gradient area.  Conversely, in a 
steep gradient area, a point maybe be separated by a large dose difference with a reference 
point, but, the spatial displacement between them might be small.  Hence, the gamma method 
                                                        
15 http://www.osl.uk.com/ 
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can be used in assessing dose difference and distance to agreement between points and is used 
to investigate the validity of a certain treatment plan.  
In Dosimetry Check, the gamma distribution is evaluated by taking the TPS as the 
reference distribution, and the dose computed by Dosimetry Check as the evaluated 
distribution.  Equation 3.5 describes the gamma method in mathematical detail,  
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where, rr and re are the reference point and evaluated point respectively.  Given the reference 
point, rr, the volume around that point is searched for the minimum gamma value Γ.  Dr (rr) is 
the dose at the reference point while De (re) is the dose at evaluation point, dm is the distance 
criterion (for example 0.3cm), DM is the dose criterion (for example 3% x 200 cGy/100 = 6 cGy). 
DM would normally be the target dose at the isocentre (Math Resolutions, 2017).  However, 
there are some practical considerations to be taken into account for the evaluation of gamma.  
Matrix spacing for dose calculation in Dosimetry Check has to be the same as the distance to 
agreement that the user has defined, since Dosimetry Check interpolates the values for gamma 
distribution on planar images.  For example, if the user defined the distance to agreement to be 
0.3cm, but the matrix spacing for interpolation in Dosimetry Check is 0.5cm, the resulting dose 
is compromised for the gamma calculation.   
 The dose algorithms utilised in this research have been discussed in this chapter.  The 
application of these algorithms to obtain the necessary data to fulfil the aims of this research 
will be explained further in subsequent chapters. 
(Equation 3.5) 
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Chapter 4  
MONTE CARLO VERIFICATION OF LINEAR ACCELERATOR AND 
TREATMENT PLANNING SYSTEM 
In this chapter, the simulation of radiation transport through a model of a local linear 
accelerator using Monte Carlo simulation techniques is described.  Parameters used for the 
simulation are discussed, as well as workflow though the validation steps.  Simulation of 
radiation output from some standard field configurations are presented and compared with 
measured data and equivalent fields generated by the local TPS, mainly to demonstrate that the 
simulation gives reliable baseline data in comparison with other techniques discussed in 
subsequent chapters. 
4.1 MONTE CARLO MODELLING OF LINEAR ACCELERATOR 
There is now a standard expectation that radiation treatment beams should be highly 
geometrically conformal and produce the most accurate dose distributions possible in relation 
to the tumour.  Modern radiation therapy equipment is increasingly capable of delivering small 
fields of arbitrary shape, as a consequence of increased availability of high-definition MLCs on 
conventional accelerators and specialised machines capable of providing IGRT, IMRT and 
VMAT treatment techniques.   
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Hence such regimes necessitate tighter target margins for clinical accuracy and require 
strict dosimetry demands.  The aim of this work was to model the linac as accurately as possible 
to provide reliable verification of the research. 
4.1.1 Determination of source size and energy photon 
In this work, the linear accelerator, which is the subject of the modelling exercise, is a 
6MV Varian 2100CD ‘TRILOGY’ system available in the Velindre Cancer Centre.  This has been 
previously modelled and validated using BEAMnrc (Rogers et al., 1995) and DOSXYZnrc 
(Kawrakow and Walters, 2006) Monte Carlo codes as part of an earlier project (Spezi and 
Lewis, 2002, Chin et al., 2003).  The model was reviewed and checked for continued accuracy 
for the purposes of the current project.  Validation of the LINAC model started with performing 
a full Monte Carlo modelling exercise, although this was intrinsically time consuming.  The 
validation process began with the determination of source size and energy of the incident 
electron beam.  A nominal energy of 6MeV and a source size of 1.0mm were chosen as starting 
points in defining the incident electron beam based on values provided by the manufacturer.   
A number of component modules such as SLABS, CONS3R, FLATFILT, CHAMBER, JAWS 
and DYNMLC were used to model features of the LINAC including target, primary collimator, 
flattening filter, ion chamber, mirror, secondary and tertiary collimators (jaws and MLC) (Figure 
4.1).   A topical review of the Monte Carlo modelling of external photon beams (Verhaegen and 
Seuntjens, 2003), suggested that tuning of the primary electron energy by comparing the depth 
dose results for a 10x10cm2 field with measured data is a necessary first step.  For this purpose, 
local commissioning data of percentage depth dose for a 10x10cm2 field taken with a 
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Scanditronix Wellhoffer CC13-S Ionisation Chamber16 (with typical active volume of 0.13cm3) 
was compared with simulated data using MC.   
A water equivalent phantom of geometry and dimensions as shown in Figure 4.2 was 
used to represent a 50x50x50cm3 water tank for dose calculation using DOSXYZnrc.  SSD was 
set to 100cm and each field size was defined at the surface of the phantom.  Analysis of the 
comparison work was carried out using the Matlab software image processing toolbox 
previously developed locally (Spezi et al., 2002).   
 
 
 
 
 
 
 
 
 
                                                        
16 Scanditronix Wellhoffer CC13-S Ionisation Chamber used for the relative dosimetry of photon and electron beams 
in radiotherapy and as a standard chamber for use in a water phantom.  
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Figure 4.1 - A preview of the linac head modelled using BEAMnrc, consisting of the main 
component modules such as X-ray target, primary collimator, flattening filter, ion chamber, 
the collimator jaws and also the MLC. (A) XZ view, (B) YZ view 
Figure 4.2 – A phantom consisting 
of water equivalent slabs was used 
in DOSXYZnrc dose calculation for 
the validation exercise. 
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In order to investigate the effect of different electron energies, depth dose curves were 
also obtained at 5.9MeV and 6.1MeV and their differences investigated.  Once the depth-dose 
energy match had been found, large field size (40x40cm2 beam) profiles were obtained to 
investigate any inconsistencies in the profile shape caused by incorrect source size.  The 
importance of finely tuning the electron focal spot size in the investigation of MC calculation 
accuracy has been described previously (Scott et al., 2008, Scott et al., 2009).  The profile (at 
shallow depth) obtained by simulation was matched against the commissioning data acquired 
using a Scanditronix Wellhoffer Photon Field Diode (PFD)17.   
Both depth doses and profiles were simulated and plotted in relation to a homogenous 
water phantom created using DOSXYZnrc. The computation was fed into the distributed 
computing RTGrid portal (described in Chapter 3) for faster calculation.  In order to fully verify 
the linac for this work, beam profiles were also plotted for smaller field sizes such as 5x5cm2, 
3x3cm2 and 2x2cm2. All the fields were then normalised to a depth of 5cm.  The early steps in 
the process of energy and field size tuning are illustrated in the flowchart in Figure 4.3. 
 
 
 
                                                        
4 Scanditronix Wellhoffer photon field diode, used for beam profile measurement in a water tank  
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Figure 4.3 - A flowchart of  the general steps involved in the initial validation process. 
A nominal electron energy of 6MeV 
and source width of 0.1 cm (1mm) 
selected as the starting point of energy 
tuning 
Profile OK? 
YES 
Source size tuning (starting with 
1mm) evaluated by consistency of 
profile at different depths at an 
adequately large field size 
Profile OK? 
YES 
VALIDATE MODEL 
NO 
NO 
Energy tuned by comparison of 
depth dose curves for a 
10x10cm2 field with the 
measured data 
Source size adjusted with 
comparison of profiles at 
different depths 
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    The key parameters used in running the BEAMnrc and DOSXYZnrc simulations are 
shown in Table 4.1 (I) and (II).  It is essential that correct parameters are used to make sure that 
the simulations are of the appropriate level of accuracy.  For that purpose, the BEAMnrc 
parameter ISOURCE=19 (Figure 4.4) was selected as the source type to match the Gaussian 
distribution of the electron beam entering the centre of the X-ray target.  This is due to the fact 
that the direction and spatial distribution of the accelerated electron beam has a significant 
effect on the angular distribution of the generated X-ray beam.  It is assumed that the trajectory 
of the electron beam within the linac is perpendicular to the surface of the X-ray target with an 
unknown spatial distribution.  From measured data elsewhere, it has been suggested that the 
spatial spread of the electron beam resembles a Gaussian distribution (Sheikh-Bagheri et al., 
2000).    
 
 
Figure 4.4 - Source type of Elliptical 
beam with Gaussian distribution in X 
and Y direction, ISOURCE=19 in 
BEAMnrc code.  A source size with 
FWHM of 0.1cm (1mm) was used in 
the simulation (From BEAMnrc User 
Manual). 
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Table 4.1 - Example of parameters used in Monte Carlo EGSnrc package ((I) BEAMnrc /            
(II) DOSXYZnrc) for the simulation of photon transport through water phantom. 
(I) BEAMnrc 
ITEM VALUE 
SOURCE BEAM ENERGY 6.00 MV  
BEAM ENERGY TYPE Monoenergetic 
ECUT 0.700 MeV 
PCUT 0.010 MeV 
BREMSTRAHLUNG SPLITTING Directional 
DBS SPLITTING RADIUS 30cm (changeable with field size selected) 
SOURCE TO SURFACE DISTANCE (SSD) 100cm 
BREMSTRAHLUNG SPLITTING NUMBER, NBRSPL 1000 
USE REJECTION PLANE None 
CM FOR E-/E+ SPLITTING 4 (FILTER) 
E-/E+ SPLITTING PLANE NO. 19 (Z=12.6153) 
Z OF RUSSIAN ROULETTE PLANE 12.6cm 
REDISTRIBUTE OF SPLIT E-/E+ ON 
AUGMENTED RANGE REJECTION  None 
BREMS CROSS-SECTION ENHANCEMENT OFF 
SPLIT ELECTRONS OR PHOTONS AT CM None 
SOURCE TYPE (ISOURCE) ISOURCE=19; source size with FWHM=1mm 
(II) DOSXYZnrc 
ITEM VALUE 
PHOTON BEAM ENERGY 6.00 MV  
ECUT 0.700 MeV 
PCUT 0.010 MeV 
MEDIUM OF PHANTOM H20521ICRU 
RANGE REJECTION ON 
HOWFARLESS ON 
SOURCE TO SURFACE DISTANCE (SSD) 100cm 
SOURCE TYPE (ISOURCE) 9 = Treatment Head Simulation 
INCIDENT BEAM SIZE 10cm 
DBS SPLITTING FIELD RADIUS 30cm (changeable with field size selected) 
SSD OF SPLITTING RADIUS 100cm 
Z WHERE SOURCE SCORED 70cm 
DISTANCE FROM SOURCE TO ISOCENTRE (SID) 30cm 
PHOTON SPLITTING NUMBER, N_SPLIT 100 
GLOBAL SMAX 5cm 
XIMAX 0.5cm 
X DIMENSION OF WATER PHANTOM 0.1mm x 500 voxels 
Y DIMENSION OF WATER PHANTOM 0.1mm x 500 voxels 
Z DIMENSION OF WATER PHANTOM 
0.1mm x 30 voxels 
0.2mm x 235 voxels 
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While the main aim of this chapter is to verify the accuracy of the linac model in 
delivering fields of interest in this work, the accelerating potential used throughout the work 
was 6MV to provide some simplicity.  ICRU 521 was selected as the cross-section dataset for the 
materials used in the simulation, with a secondary electron production cut-off of 10keV (see 
details in Chapter 3).  It contains physical properties such as mass density, electron density and 
atomic number of the materials that make up the component modules as set out in ICRU report 
37 (ICRU 1984).  ECUT (electron cut-off) and PCUT (photon transport cut-off) were set to 
0.7MeV and 0.01MeV respectively to increase the accuracy and efficiency of the simulation as 
much as possible (Seco and Verhaegen, 2013). This meant that those electrons and photons 
whose energy fell below these values were discarded from the simulation and any remaining 
energy was deposited to the current region in the simulation.   
Another important factor that can significantly increase the efficiency of the simulation 
is the application of the directional bremsstrahlung splitting (DBS) (Kawrakow et al., 2004) 
parameter compared to uniform or selective splitting (UBS or SBS).  With DBS, bremsstrahlung 
photons which fall into a field of interest are split as they are created, while those out of the field 
are not.  The magnitude of the DBS parameter is variable and dependent on the energy and 
other details of the beam.  For this work, DBS was set to 1000 (Kawrakow et al., 2004) while its 
splitting radius was set to 10cm in both BEAMnrc and DOSXYZnrc for a 10x10cm2 field.  It was 
varied for other field sizes to avoid ‘fat’ photons being included in the region of interest.  
As a further step in the validation of the linac model, correction for backscatter radiation 
from the Varian linac collimator jaws into the monitor chambers has been shown previously to 
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be an essential part of the process.  From the literature, the effect of the backscatter radiation 
has been shown to be small compared to that due to head scatter and phantom scatter.  
However, in order to achieve accurate dose calculation, it is important to include this correction 
when using the convolution algorithm or any other model-based methods including MC (Liu et 
al., 1997a, Liu et al., 1997b).  Moreover, the use of advanced treatment techniques such IMRT 
using dynamic jaw movement requires the photon output to be predicted with a high degree of 
accuracy for individual component fields.  Hence, it is important to investigate the cause of 
variation in photon output in relation to the field collimation.   
The method devised by Liu et al. (2000) was used for the correction of backscatter from 
the jaws for this work.  In this method, MC simulations were used to estimate the ratio of 
backscatter radiation to the forward radiation R (x, y) scored at the monitor chamber by 
investigating the amount of backscatter radiation as a function of X and Y jaws individually as a 
compound contribution to the photon output.  R (x0, y0) is the ratio of backscatter radiation from 
a reference field (10x10cm2).  The dose ratios R (x, y) were then used to calculate the change in 
photon output caused by the backscatter, Scb (x, y).  Data from this study showed that the 
backscattered radiation contributes approximately 3% to the monitor-chamber-scored dose.  
Mathematically, the calculation for the correction follows Equation 4.1:        
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4.1.2 Results 
From Figure 4.5, it is apparent that excellent agreement between the simulation and 
measured data of percentage depth dose (PDD) for a standard field size (10x10cm2) was 
achieved, giving percentage differences within 1% beyond the build-up region (after dmax).  This 
statement is supported by the results of PDD calculations for two slightly different energies 
(5.9MeV and 6.1MeV) as illustrated in Figure 4.6.  PDD simulation using a 6.0 MeV electron 
beam gave better (i.e. smaller) overall percentage difference than the other electron beam 
energies.  For the 6.0 MeV electron beam, the percentage difference clearly fluctuates around 
0% and is not more than 1%, while values for the other beams are more offset from the 
horizontal (0% difference) axis.  The normalisation of depth dose curves was done to a point at 
a depth (5cm in water in this work) that was appropriate to avoid effects due to an unstable 
state at dmax caused by variable electron contamination.  Point dmax is always subsequently 
rescaled to the value of 100% unless stated otherwise in the thesis.   
 
 
 
 
 
 
CHAPTER 4: MONTE CARLO VERIFICATION OF LINEAR ACCELERATOR AND TREATMENT PLANNING 
SYSTEM 
88 
 
Percentage Depth Dose for 10x10cm2 (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 – (a) MC simulation of PDD for a 6MV photon beam energy with field size 
10x10cm2 compared to measurement data, normalized at 5cm depth.                                           
(b) Relative percentage difference between the MC simulation and the measurement data.  
The simulation uncertainty is within 2%. 
(a) 
(b) 
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Figure 4.6 – (a) Depth dose curve comparison between measured data and MC data for 3 
primary electron beam energies (5.9MeV, 6.0MeV and 6.1MeV).  (b) Fluctuation of percentage 
difference for the 3 beam energies. 
Relative difference for 5.9MeV, 6.0MeV and 6.1MeV (%) 
(a) 
(b) 
PDD for 10x10cm2 (5.9MeV) 
PDD for 10x10cm2 (6.0MeV) 
PDD for 10x10cm2 (6.1MeV) 
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To check the accuracy of source size modelling, the behaviour of a large field size at a 
shallow depth is presented in Figure 4.7.  A field size of 40x40cm2 (linac maximum) is large 
enough to reveal any significant discrepancies in simulation for a 6MV photon beam.  From the 
figure, the agreement for cross-plane profiles was deemed excellent (i.e. within 2%) when 
comparing measured and calculated relative dose at dmax and 5cm depth.  A ‘zoomed’ plot 
(Figure 4.8) shows some degree of variation of agreement in the dose distribution along the 
beam profiles.  This is not unusual for large fields since they are sensitive to scattered radiation 
and variation in primary photon energy across the field due to ‘beam hardening’ from the 
flattening filter.  
Since the MC simulation and measured data were in good agreement, it was felt there 
was no need to undertake further investigation on source-related parameters for the purposes 
of this study. 
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Figure 4.7 - Beam profiles for a 40x40cm2 field in the ‘X’ direction at two shallow depths in a 
water phantom (dmax and 5cm).  Good agreement achieved between simulation and measured 
data with a percentage difference of less than 2% in the high dose region.   
 
Figure 4.8 - Clear graphic of profile shape (zoomed plot from Figure 4.7) for viewing the 
matching between simulation and measurement.  The ‘horns’ and ‘dip’ on the simulation 
profiles were found to be fairly consistent with measurement profiles (uncertainty within 2%).   
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Subsequently, an analysis of a range of beam profiles was performed by comparing 
measured and simulated data for several example field sizes.  This showed excellent agreement 
in both X and Y directions for varying depths (Figure 4.9).  Furthermore, the PDD analysis for all 
the field sizes revealed percentage differences of less than 2%, also demonstrating a good 
match between simulation and measurement as shown in Figure 4.10. 
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Figure 4.9 – Dose profile comparisons for varying field size at 1.5cm (dmax), 5cm, 10cm, 20cm and 30cm 
depth for 6MV photon beam energy, at 100cm SSD.  All the profiles were normalised to 5cm deep 
(2x2cm2 and 5x5cm2) and to 10cm (10x10cm2). 
(a) 2x2cm2 profiles in ‘x’ direction (b) 2x2cm2 profiles in ‘y’ direction 
(c) 5x5cm2 profiles in ‘x’ direction (d) 5x5cm2 profiles in ‘y’ direction 
(e) 10x10cm2 profiles in ‘x’ direction (f) 10x10cm2 profiles in ‘y’ direction 
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Figure 4.10 - MC simulation of PDD for various field sizes showing agreement with the 
measurement data and giving percentage difference of less than 2%.  Percentage depth 
dose applied in order to retain the dose relative to dmax.    
 
Relative difference for 2x2cm2 (%) 
Relative difference for 5x5cm2 (%) 
Relative difference for 40x40cm2 (%) 
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The results of the analysis of backscatter from the collimator jaws into the monitor 
chamber, before and after correction using the method devised by Liu et al., is shown in Figure 
4.11.  With this correction included, the output factor significantly improved in terms of the 
agreement between MC simulation and measured field size output factors for the 6MV photon 
beam energy.  The correction factors varied from 1.13 for the smallest field size (2x2cm2) to 
0.91 for the largest field size (40x40cm2).  Data were normalised to a reference field size 
(10x10cm2). 
 
 
 
 
 
 
 
            
             
 
Figure 4.11 - Field size output correction factors generated by MC simulation against the 
measurement output factors (OF) before and after correction for backscatter from the collimators.  
Note: blue labels – OF before correction, yellow labels - OF after correction.  Good agreement of OF 
after correction with OF from measurement (solid black line) were achieved. 
 
Field size (cm) 
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4.1.3 Discussion 
From the data presented in this validation work, simulated depth dose and dose profile 
plots were shown to be in a very good agreement with the measurement data (Figure 4.5 to 
Figure 4.10).  All experimental data for depth doses were measured using a Scanditronix 
Wellhoffer CC13-S Ionisation Chamber.  A Scanditronix Wellhoffer photon field diode was used 
for beam profiles across a 50x50x50cm3 water tank. 
During the matching procedure, normalisation of depth doses and dose profiles 
between measurement and Monte Carlo simulation were done using a scaling factor which 
referred to a percentage depth dose in the central axis, in order to retain the dose relative to its 
maximum value.  Hence, the maximum dose will always be 100% (unless stated otherwise).  
Finally, the optimum photon energy that best represents the linac model in this work (nominal 
6MV) corresponds to a 6.0 MeV primary electron energy and 0.1cm electron beam width.   
4.2 MLC AND EPID MODELLING 
There are variety of MLCs available across a range of linacs, which provide the 
necessary performance and accuracy for improving treatment verification and delivery.  For 
this accelerator modelling, a Millennium 120 MLC (Figure 4.12), which has ‘tongue-and-groove’ 
construction to minimise radiation transmission between adjacent leaves (Mayles et al., 2007), 
was used (as it forms part of the Velindre Cancer Centre Varian 2100CD Trilogy unit).  The MLC 
is one of the component modules (DYNVMLC) from the original modelling work of Heath and 
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Seuntjens (2003).  It consists of 40 inner leaves and 20 outer leaves for each bank and the width 
projects to 0.5 cm and 1.0 cm, respectively, at the isocentre distance.  The MLC leaves move 
perpendicular to the radiation beam.  Tungsten based alloy is the most suitable material of leaf 
construction as it has the highest density of most metals.   The maximum field size that can be 
modulated using the Millennium 120 MLCs is 20x20cm2, which allows an IMRT segmented 
beam of less than this size. 
During its initial release within BEAMnrc (Heath and Seuntjens, 2003), the model only 
allowed for ‘static’ mode MC calculation.  Later, the introduction of a ‘step-and-shoot’ simulation 
mode enabled multiple segmented IMRT beams to be simulated in a single calculation run.  
Within the Velindre Cancer Centre, the modelling of this DYNVMLC CM has been validated by 
previous work (Cufflin et al., 2010).   
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Figure 4.12 - (a) VARIAN Millennium 120-leaf MLC, Source: Varian Medical System.              
(b)Detailed cross-section of the three leaves construction of the VARIAN Millennium 120-leaf 
MLC; DYNVMLC component module, Source: (Rogers et al., 2011). 
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Previous work has highlighted the suitability and efficiency of Monte Carlo as a ‘gold 
standard’ method in modelling the radiotherapy beam and its good correlation with phantom 
measurement in verifying the transmission dose through to the EPID.  In some studies, the 
results of the experimental and measured data matched the gamma criterion within 3%/3mm 
for beam profiles in most IMRT clinical treatments (Blake et al., 2013, Blake et al., 2014). 
With regard to IMRT, which intrinsically involves irregular segmented fields with very 
steep dose gradients, an effective method of verifying IMRT plans during treatment delivery 
using EPIDs has been discussed by Cufflin et al. (2011).  Their results showed that MC 
calculations of exit dose in water-equivalent material at the EPID level verified the ability of the 
TPS to calculate the dose correctly for this situation.  Nowadays, there is wide recognition of the 
ability of the EPID to perform 3D in vivo dosimetry and to give more useful clinical results than 
a pre-treatment verification of the patient plan (Mijnheer et al., 2013a, Mijnheer et al., 2013b, 
Mijnheer et al., 2017).  This EPID-based approach is believed to be able to identify most of the 
patient-specific errors due to anatomical changes or deviations from routine clinical procedure, 
i.e. the ones that intrinsically cannot be detected by pre-treatment verification. 
Throughout this research, the Varian imager is the PortalVision aS1000 EPID mounted on 
a support arm of the Varian 2100CD Trilogy linac.  In this section, no further work is carried out 
to validate EPID portal dosimetry, since this has already been done in a previous project (Cufflin 
et al., 2009, 2010) and the main aim of this chapter is to produce an accurate model of the linac 
output that can be used for comparative purposes for the rest of the work described herein.   
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4.3 MONTE CARLO SIMULATION ACCURACY AND EFFICIENCY 
4.3.1 Uncertainty and Variance Reduction Techniques  
Within BEAMnrc and DOSXYZnrc, the statistical method for fluence calculation and 
estimating uncertainty is based on the history-by-history approach described by Sempau et al. 
(2001).  The estimation of the uncertainty of a scored quantity X is given by: 
 
 
where Xi is the quantity scored in a statistically independent event i (i.e. history i) and N is the 
number of independent events, i.e. histories. 
As a result of using Equation 4.2, the problem of small sample size is eliminated.  N is 
now the number of histories which is large enough to be statistically analysed, rather than the 
number of batches (usually 10) as before in the old BEAM code method of uncertainty 
estimation. 
Figure 4.13 demonstrates the relationship between the number of histories and MC 
simulation time (Central Processing Unit, CPU time) for 100cm SSD, 30x30x30cm3 
homogeneous voxel water phantom and 2MeV mean electron energy, using 1 Million particle 
histories (1x106) as a starting point.  The CPU time taken to finish the simulation obviously 
increases with increasing number of histories as more time is taken to track the particle 
(Equation 4.2) 
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trajectories.  For simplicity, these particular MC simulations were performed using a personal 
computer with Intel (R) Core i5-3317U, 1.70GHz processor.    
 
 
 
 
 
 
 
 
 
 
As the accuracy of Monte Carlo calculation is limited by its statistical uncertainty, 
Variance Reduction Techniques (VRTs) are often used to decrease the calculation time by 
modifying the algorithm while ensuring that the results of MC do not deviate systematically 
from the corresponding results without VRT (Verhaegen and Seuntjens, 2003).  Hence, the 
Figure 4.13-The relationship between MC calculation time, T (hour) and Uncertainty, σ 
(%) with increasing number of histories, N. 
CHAPTER 4: MONTE CARLO VERIFICATION OF LINEAR ACCELERATOR AND TREATMENT PLANNING 
SYSTEM 
101 
 
efficiency of MC simulation with VRTs is often optimised to minimize the calculation time 
without modifying the results of the simulation.  The simulation Efficiency ε, is defined by 
Equation 4.3.      
( )  ( )NTNS 22
1
=  
where S(N)2 is the average variance from the simulation of a region of interest (central axis 
depth dose distribution in a water phantom) and T(N) is the average CPU time for a particular 
job to finish (Ma et al., 2005, Mohammed et al., 2016).  During this validation work, some basic 
VRTs were used to speed up the calculation time and increase the efficiency of the simulation.  
These were determined beforehand and used as simulation set-up parameters using the 
Velindre Cancer Centre RTGrid portal (detailed in Chapter 3).   
The bremsstrahlung splitting number, NBRSPL, and the particle splitting number, 
N_SPLIT, in BEAMnrc and DOSXYZnrc respectively, were used to create a large number of 
photons to minimise the statistical uncertainty while reducing the time required for the 
creation of the split photons.  For this work, a NBRSPL of 1000 was used in all simulations as it 
has been reported to give the highest efficiency (Kawrakow et al., 2004, Rogers et al., 2011).  
The N_SPLIT value was set to 100 since it was shown from the initial experiment to lie between 
75 and 125 for the modelled accelerator (Figure 4.15).  Simulation efficiency was calculated 
using Equation 4.3.  The optimum N_SPLIT value (of 100) improved efficiency by a factor of 29 
when compared to simulations with no splitting (Figure 4.14).  Hence, this value is used 
(Equation 4.3) 
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throughout the MC simulations.  The number of events was set to be 4x108 histories for 
0.2x0.2x0.2cm3 voxel dimensions in a homogeneous water phantom.   
 
 
 
 
 
  
 
 
As a specific exercise linked to the main aim of this research (discussed in subsequent 
chapters) some validations were required for elongated rectangular field sizes, e.g. 5x30cm2, 
using MC simulation.  These data were then compared to experimental data obtained from the 
LA5 commissioning using a Scanditronix Wellhoffer CC13-S Ionisation Chamber in a 
50x50x50cm3 water tank.  The simulation used 4x108 histories in a 40x40x30cm3 water 
phantom with 6MV photon energy.  Dose distributions at different depths were normalised to 
the central axis depth doses for an equivalent square field corresponding to 5x30cm2 
Figure 4.14 - N_SPLIT relationship with the efficiency of simulation. 
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(approximately 8.5cm) and to retain the maximum dose at dmax (100%).  The results of the 
experiment are presented in Figure 4.15. 
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 Figure 4.15 - ‘X’ and ‘Y’ profile comparison between MC and Ionisation Chamber measurement (IC) for 
5x30cm2.  All profiles were normalised to central axis depth doses in order to retain the value of 100% at 
dmax.  Good agreement was achieved within ±2% in the high dose region. 
 
Beam profile of 5x30cm2 Beam profile of 5x30cm2 
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4.4 VERIFICATION OF OMP USING MONTE CARLO SIMULATION 
The accuracy of dose calculation algorithms implemented in a TPS can be verified by a 
variety of phantom measurements and techniques.  The QA measurements for a typical 
patient’s treatment plan are normally performed at a reference point using an Ionisation 
Chamber or 2D detector array in a phantom.  Although some 3D detector solutions (e.g. gel 
dosimetry) have been developed in the research domain, they ultimately require a realistic (i.e. 
heterogeneous) phantom geometry to record the dose accurately.  As a complementary 
approach, MC methods can also be used to represent the patient’s CT scan or heterogeneous 
patient geometry with a high degree of accuracy.  There are many published results on dose 
comparison between Monte Carlo and various TPSs highlighting MC as an effective IMRT QA 
verification tool (Ma et al., 2000, Li et al., 2001, Francescon et al., 2003).    
While Monte Carlo is proven as a ‘gold standard’ dose calculation algorithm, in practice, 
it requires extra computational time, although in some centres it has been configured to be an 
automated QA system (Leal et al., 2003).  In Velindre Cancer Centre, both PB and CC 
approximation algorithms are employed in the Oncentra MasterPlan (Nucletron) TPS for most 
of the treatment plans, though CC now predominates for clinical use.  Details on the dose 
calculation algorithms have been discussed in Chapter 3.   
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4.4.1 Methods 
In this section, the BEAMnrc and DOSXYZnrc Monte Carlo packages are considered as 
benchmark tools in assessing the validity of on-site OMP dose calculations.  First, a simple set of 
square field sizes (3x3cm2, 5x5cm2 and 10x10cm2) was used to provide comparison between 
MC and OMP while applying the same voxel dimension on a water slab phantom with 100cm 
SSD.  
The validation of the on-site treatment planning system was also performed with Monte 
Carlo simulation of a sequence of 6MV Head-and-Neck IMRT beams in a water slab phantom 
and profile comparison was done against the OMP dose calculation.  A calibration factor was 
required to convert MC simulation to dose.  To do this, simulation of 10x10cm2 field size in a 
water phantom at SSD 100cm was performed to find the energy deposited per unit mass, per 
incident particle (the unit from the result of MC simulation), at a reference point (in this case 
10cm deep in a water phantom) at which the dose from 100MU is known.  Note that, 
extended voxels of ~2cm around the central axis of the 10x10cm2 field were averaged to avoid 
the calibration value being affected by the statistical uncertainty of the value in a single voxel.  
The calibration factor was then applied to following IMRT simulations to get dose per MU 
delivered to the water slab phantom.  The experiment was further evaluated with 2D gamma 
for a 20% dose threshold so that the results were representative of the area of the treatment 
field.  Percentage of points within the field passing a range of gamma criteria were calculated 
with the aid of Matlab programming.  This Head-and-Neck clinical case will be later used in the 
Dosimetry Check comparison as detailed in Chapter 5 and Chapter 6. 
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As calculated previously using Equation 4.5, a backscatter factor from the jaws into the 
monitor chamber was also included as part of the calculation to get the dose.  Mathematically, 
the MC dose was calculated as: Monte Carlo dose (Gy) = (MC raw value/Calibration factor) 
x (BSF) x (Field Monitor Unit) where BSF is the backscatter factor from the jaws. 
4.4.2 Results 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 – Comparison of percentage Depth Dose curves for 10x10cm2 field between  
OMP, MC simulation and Ionisation Chamber measurement.  Excellent agreement was 
found (less than ±1%).  Plotted curves were normalised to 5cm depth and PDD was used 
to retain the dose distribution of maximum dose along the central axis. 
Percentage Depth Dose of a 6MV photon beam for 10x10cm2 field 
CHAPTER 4: MONTE CARLO VERIFICATION OF LINEAR ACCELERATOR AND TREATMENT PLANNING 
SYSTEM 
108 
 
Figure 4.16 shows excellent agreement between OMP and MC simulation with ±1% 
depth dose difference beyond the build-up region, in a three-way comparison (involving OMP, 
MC and ionisation chamber measurements).  Similarly, the evaluation of the OMP dose profiles 
relative to MC profiles for the simple field sizes further validated the Treatment Planning 
System (OMP) convolution algorithm in these cases.  The results of the profile comparison are 
shown in Figure 4.17 (MC vs. OMP) and Figure 4.18 (OMP vs. I.C) for 10x10cm2, 5x5cm2 and 
3x3cm2 fields.  Dose differences are within ±2% in the high dose region. 
 For two beams (B01 and B05) in the example IMRT Head-and-Neck case, good 
agreement was seen between the MC simulation beam profiles and the OMP dose profiles in 
high dose regions, where dose differences were within 3% as shown in Figure 4.19 and Figure 
4.20.  However, there was some dose disagreement in the penumbra regions. 
 The gamma index pass rates for B01 and B05 are shown in Table 4.2.  Figure 4.21 shows 
representative 2D gamma maps with excellent agreement of 90.8% and 96.9% for points 
passing the 4% 4mm gamma criterion for B01 and B05 respectively.  For the 3% 3mm 
criterion, the corresponding values are 84.1% and 88.4% respectively.  These results are 
reasonably consistent with the 85% recommendation for acceptance given in ICRU 83 
(ICRU,2010) for the percent of pixels within a 3% and 3mm threshold in gamma analysis for a 
complex plan such as Head-and-Neck IMRT.   
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Figure 4.17 - ‘X’ and ‘Y’ profile comparison between MC and OMP TPS for 10x10cm2, 5x5cm2 and 3x3cm2 fields.  All profiles were normalised to 5cm depth. 
X distance from the centre (cm) Y distance from the centre (cm) X distance from the centre (cm) Y distance from the centre (cm) 
X distance from the centre (cm) 
Y distance from the centre (cm) 
(a) 10x10cm2 (b) 5x5cm2 
(c) 3x3cm2 
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Figure 4.18 - ‘X’ and ‘Y’ profile comparison between IC and OMP TPS for 10x10cm2, 5x5cm2 and 3x3cm2 fields.  All profiles were normalised to 5cm depth. 
X distance from the centre (cm) Y distance from the centre (cm) X distance from the centre (cm) Y distance from the centre (cm) 
X distance from the centre (cm) Y distance from the centre (cm) 
(a) 10x10cm2 (b) 5x5cm2 
(c) 3x3cm2 
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 Figure 4.19 – Example of MC simulation of IMRT beam (B01) of Head-and-Neck case compared to the dose calculated by on-site treatment planning.  (a) B01 
IMRT beam showing the cut along profile; cross-line profile (white dotted line) and in-line profile (green dotted line). (b) cross-line and (c) inline profiles 
comparison between dose simulated by MC and dose calculated by OMP TPS.  The two profiles are in a good agreement; dose differences are within 3% in high 
dose regions. 
(a) 
(b) (c) 
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(a) 
(b) 
(c) 
Figure 4.20 - Example of MC simulation of IMRT beam (B05) of Head-and-Neck case compared to the dose calculated by on-site treatment planning.  (a) B05 
IMRT beam showing the cut along profile; cross-line profile (white dotted line) and in-line profile (green dotted line). (b) cross-line and (c) inline profiles 
comparison between dose simulated by MC and dose calculated by OMP TPS.  The two profiles are in a good agreement; dose differences are within 3% in high 
dose regions. 
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Table 4.2 – Gamma passing rates for example of IMRT Head-and-Neck MC simulation for OMP 
TPS verification result.    
 
 
 
 
 
Gamma 
Criteria 
Gamma passing rates for IMRT beam (%) 
B01 B05 
3%, 3mm 84.1 88.4 
3%, 4mm 88.0 92.8 
3%, 5mm 91.3 97.5 
4%, 3mm 88.0 92.9 
4%, 4mm 90.8 96.9 
4%, 5mm 93.6 99.0 
5%, 3mm 90.8 95.7 
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(a) B01  
(b) B05 
Figure 4.21 – Examples of 2D gamma maps for IMRT Head-and-Neck beams showing 
percentage of points passing two different gamma criteria, 3%, 3mm and 4%, 4mm.          
(a) B01 and (b) B05    
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4.4.3 Discussion 
All plans in this work have been optimised using the OMP TPS.  The results for the 
simple fields that were used to compare the OMP TPS against Monte Carlo calculation (section 
4.4.1) and ionisation chamber (IC) measurement revealed good agreement to within ±2% in 
high dose regions.  In addition, the validity of OMP was further investigated by Monte Carlo 
simulation of segmented IMRT fields used in the Head-and-Neck test case discussed in 
subsequent chapters.  The dose differences found were relatively small (typically 3%) and 
consistent with the tolerances applied for clinical IMRT at the Velindre Cancer Centre.  
While it cannot be denied that MC is a state-of-art method for the verification of 
treatment planning, there are many and various complexities in accurately modelling clinical 
cases using MC on patient CT datasets as discussed by several authors (Keall et al., 2001, Chetty 
et al., 2007, Chetty, 2008, Ma and Li, 2009, Jabbari, 2011).   
Furthermore, detailed MC-based validation of the local OMP system for IMRT has been 
undertaken in a previous study (Cufflin et al., 2010, Cufflin, 2012).  The present validation work 
gives contemporary confirmation and provides a good degree of confidence that the OMP 
system remains a sufficiently accurate platform for comparison with Dosimetry Check as 
discussed in subsequent chapters. 
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Chapter 5  
COMMISSIONING OF DOSIMETRY CHECK FOR VERIFICATION OF 
ADVANCED RADIOTHERAPY 
5.1 DOSIMETRY CHECK PERFORMANCE 
The aim of this chapter is to introduce the current application of the software-based 
EPID verification system, Dosimetry Check.  It also explicitly addresses the main motivation of 
the research, which is to improve verification accuracy by introducing into the existing 
Dosimetry Check system a novel correction method for backscatter from the EPID arm.  Some 
of the concepts which apply to Head-and-Neck IMRT are also be discussed in this chapter. 
 5.1.1 Dosimetry Check as an IMRT/VMAT verification tool 
Dosimetry Check is a one of a number of software systems currently being used in 
various radiotherapy centres in conjunction with EPIDs to verify the accuracy of treatment 
delivery.  It is a stand-alone piece of application software intended to work with modern linacs 
equipped with EPIDs.  Dosimetry Check was developed by Math Resolutions18, and is currently 
(2017) distributed by OSL Ltd. in the UK.  The software is advertised as being capable of 
                                                        
18 http://www.mathresolutions.com/rtqasys.htm 
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providing pre-treatment and in-vivo transit dosimetric QA information for IMRT/VMAT and 
conformal radiotherapy treatments.  The system works using an in-air fluence map, calculated 
from data recorded by the portal imager, to reconstruct a 3D dose distribution using the 
planning CT dataset.  The dose reconstructed in Dosimetry Check can then be compared against 
the dose in the original patient treatment plan.  The system is based on the original work of 
Renner et al. (2003, 2005).  IMRT/VMAT treatment verification has become a major topic of 
interest among radiotherapy researchers and practitioners (Renner et al., 2003, Mijnheer et al., 
2013a, 2013b), especially as regards 3D EPID-based patient-specific dose verification. 
Dosimetry Check uses a pencil beam dose calculation algorithm (Chapter 3) with 
fluence distribution, derived from the EPID image, as its input. It is intended to be a part of the 
patient-specific QA system to compute and verify dose delivered to the patient.  This measured 
source model (Renner et al., 2005, Math Resolutions, 2017) used in Dosimetry Check inherently 
accounts for leaf leakage, position and movement.  An EPID image of a standard (10x10cm2) 
field size is used for calibration.  Each pixel on the patient’s EPID image is then mapped relative 
to this calibration intensity, forming a ‘Relative Monitor Unit’ map.  Each of the pixels on the 
Relative Monitor Unit image is back-projected on to a plane in front of the patient and the PB 
algorithm is then forward calculated and used as an individual ‘weight’ to derive the fluence 
map.  
The PB is divided into small ‘subrays’ to calculate the radiation energy that each ray 
deposits throughout the 3D representation of the patient.  This process directly determines the 
dose to the patient in cGy.  Dosimetry Check provides a variety of dose analysis facilities such as 
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2D and 3D multiple point doses, comparison between 2D and 3D isodose distributions and 
Gamma evaluation with Dose Volume Histogram (DVH) comparison. 
EPID-based verification with the aid of Dosimetry Check software is also expected to 
improve on-set verification time compared to the use of diodes, along with the advantages of 
having multi-dimensional information, high resolution and high levels of reproducibility (Greer, 
2013).  As previously discussed in Chapter 2, the ‘Towards Safer Radiotherapy’ report (The 
Royal College of Radiologists, 2008(a)) recommended the need for in-vivo dosimetry as a 
routine protocol in every UK centre, in order to make sure each patient correctly receives the 
planned dose.  This work aims to investigate, and where possible improve, the verification 
accuracy of Dosimetry Check for better performance in pre-treatment and in transit dosimetry.  
Further details of the work are given in section 5.3.   
As an implementation of in-vivo verification, Dosimetry Check has been utilised by a 
number of centres and is claimed to be a reliable verification tool.  Pinkerton et al. (2010) 
described their clinical experience of the practicality of Dosimetry Check in verifying IMRT and 
RapidArc in pre-treatment QA.   Excellent agreement was found (within ±1%) for reference 
point doses in a multiple field pre-treatment prostate case and within ±2% for an exit 
dosimetry Head-and-Neck case. 
Similarly, as identified by Gimeno et al. (2014), typical discrepancies between 
Dosimetry Check dose and TPS dose in early commissioning are less than 2% in homogeneous 
phantoms, but greater in the presence of heterogeneities (reaching up to 15%).  Discrepancies 
are also found in transit dosimetry due to the inability of Dosimetry Check to properly include 
the couch attenuation and air gap between the patient and couch into the kernel (Gimeno et al., 
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2014).   In clinical experience, Dosimetry Check performance has been evaluated and compared 
with TPS using conventional detectors (MOSFET), and the results showed that deviation 
between MOSFET and Dosimetry Check relative to TPS was about 3% (Fafi et al., 2013).   
Commissioning and validation work published by the Clatterbridge Cancer Centre, UK 
demonstrated Dosimetry Check to be an efficient platform for in-vivo dosimetry based on its 
advantages in providing volumetric dose delivery information.  Tests were done on almost all 
their linacs (Varian and Elekta).  There was excellent agreement, in general within 1% standard 
deviation, with TPS calculations (Reilly et al., 2013).   
In spite of the evidence of good performance mentioned above, confidence in Dosimetry 
Check for clinical use must be gained locally by clinical staff, especially radiographers and 
physicists, in the hospital.  Therefore, Dosimetry Check commissioning and necessary to ensure 
accuracy of the reconstructed dose for each patient who receives radiotherapy.  
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 5.2 COMMISSIONING AND VALIDATION OF DOSIMETRY CHECK IN VCC 
The set-up of Dosimetry Check for use with a local linac (Varian Trilogy ‘LA5’) at 
Velindre Cancer Centre was initially undertaken during 2014 by the physics team.  This 
involved infrastructure configuration to enable Dosimetry Check to run on the hospital system, 
including the introduction of a Citrix19 application server setting, which allowed the use of 
Dosimetry Check through the hospital network.  By September 2015, the commissioning work 
had finished, and a pilot study started, prior to introducing Dosimetry Check for clinical use in 
January 2016.  
Initially, measurement data were taken with LA5 at gantry 0° using a water tank 
(supplied by OSL, UK) at depths ranging from 0-50cm in order to generate the dosimetric 
information required to configure the required deconvolution kernels.  The data were then sent 
to OSL UK and full commissioning began upon receiving the kernels from OSL.  The 
commissioning started with the acquisition of data for a series of basic square fields ranging 
from 5x5cm2 to 20x20cm2 and verification at different gantry angles and different energy 
settings (6MV and 10MV).  The commissioning involved data from anthropomorphic pelvic and 
lung phantoms, as well as 27 patient cases to validate the results obtained.   
                                                        
19 Citrix Systems - software designed to provide server, application and desktop visualisation, networking, and cloud 
computing technologies to remote to hospital network. http://en.wikipedia.org/wiki/Citrix_Systems 
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5.2.1 Results 
Results of the initial commissioning process varied according to the type of case used.  
For transit dosimetry using simple geometries and a water medium, Dosimetry Check gave 
1.5% difference to TPS dose at the isocentre for a 10x10cm2 field at gantry angle 0 .˚  However, 
the dose difference increased to 2.5% compared to TPS for 6MV photon energy at gantry angle 
270 .˚  The greater discrepancy was later identified as being due to an incorrect kernel, which 
had not taken into account couch attenuation in the initial water tank measurement.  Couch 
factors have been reported to influence treatment delivery dose because of attenuation of the 
photon beam, especially at increasing obliquity (Munjal et al., 2006, van Prooijen et al., 2010, 
Olch et al., 2014).    
Later in August 2015, new (corrected) deconvolution kernels were obtained from 
OSL/Math Resolutions, which accounted for the couch.  It was confirmed that couch attenuation 
had been excluded in their previous kernels and hence this explained the dose deviation cited 
above.  The new deconvolution kernels incorporated 0.4cm water equivalent material 
representing the couch.  With the correct kernels, a sub-set of commissioning tests were 
repeated, and the results improved as summarised in Figure 5.1 (a, b).   
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(a)                                              (b) 
                                      
 
 
 
 
 
 
 
 
Some systematic errors were evident in Dosimetry Check commissioning, arising from 
the effect of non-uniform backscatter from the Varian imager support arm located at the Gantry 
side of the G-T20 direction.  Hence, when an image is acquired with a large flood-field (covering 
the whole imager area), the backscatter effect is not readily apparent.  This is because the same 
backscatter is present in both the acquired and the flood-field images, thus cancelling each 
other out.  However, since scatter conditions vary with field size (Cufflin et al., 2010), when the 
field size changes there will be a mismatch in the scatter for both images, hence backscatter 
becomes apparent.  This condition is likely to be insufficient to ensure accurate verification of 
small off-axis fields and narrow rectangular fields for example (Figure 5.2). 
                                                        
20 G-T direction – is defined as Gun-Target or ‘in-line’ direction of electron travel in a linac set-up 
Gantry 
angle 
Energy 
6MV 10MV 
0° -0.3% +1.0% 
90° +1.6% +1.0% 
270° +1.7% +1.0% 
360° +0.4% +0.5% 
Figure 5.1 - (a) Results of the repeated sub-set of commissioning test with the improved 
kernels from Math Resolutions giving excellent agreement between DC and Oncentra 
MasterPlan TPS.   
(b) Water slab phantom modelled in OMP with added 0.4cm water equivalent material 
representing the couch. 
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Following the local commissioning phase for LA5, Dosimetry Check was approved for 
use to verify conformal plans except for Head-and-Neck IMRT (due to the relatively poor results 
found in the initial commissioning).  Further investigation was required in the anticipation that 
correcting for non-uniform backscatter would improve these results, enabling them in due 
course to be verified clinically.  Investigation work in Velindre Cancer Centre continues with the 
eventual aim of utilising Dosimetry Check for all plans, including verification of Head-and-Neck 
IMRT and arc treatments (Chapter 6).    
5.2.2 Clinical implementation 
Since January 2016, Dosimetry Check has been in clinical use on a single linac (LA5) in 
Velindre Cancer Centre for all conformal treatments (mostly breast patients) but excluding 
Head and Neck IMRT.  The steps in the process include importing and exporting the necessary 
patient file information using a network between Dosimetry Check and TPS as illustrated in the 
Figure 5.2 - Non-uniform backscatter from VARIAN imager arm for different field sizes. Effect 
clearly significant in 3x20cm2 (narrow field size) relative to a standard flood-field calibration.  
Images of beam profiles were part of the report of the internal commissioning for Dosimetry 
Check on LA5 at Velindre Cancer Centre. 
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flow diagram in Figure 5.3.  Physicists have responsibility for confirming that a request for 
images has been made and responding to any ‘out of tolerance’ results on the dose comparison 
between Dosimetry Check and TPS reported by radiographers.  The tolerance levels being used 
currently are ±5% for all conformal plans and -5% to +10% for breast (as the Dosimetry Check 
PB algorithm over-responds when calculating oblique breast fields on the patient CT scan).   
The Dosimetry Check report includes analysis of dose comparison with TPS using a 
variety of approaches including 2D dose profiles with isodose distribution map, DVH and 
Gamma Volume Histogram (GVH)21, which can be selected within Dosimetry Check.  For initial 
routine use, Velindre Cancer Centre has clinically implemented point dose comparisons and 
occasionally 1D dose profiles and isodose distributions.  Full gamma analysis is not yet realistic 
due to asymmetry caused by non-uniform backscatter.  
 
 
 
 
 
                                                        
21 Gamma Volume Histogram – represents the cumulative passing rate for a volume defined in TPS, which consists of 
multiple 2D planes within the volume. 
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Figure 5.3 - A flow diagram representing the process involved in conformal/IMRT 
treatment verification using Dosimetry Check software. 
Patient information files such as CT images/RT structures/RT 
plans/RT dose matrix from TPS exported to Dosimetry Check 
system 
Patient treatment images acquired with EPID for all 
conformal/IMRT treatments 
Calibration file for 10x10cm
2
 field is applied to the EPID images to 
generated Relative Monitor Units (RMU) 
Report is generated by Dosimetry Check, compared against TPS 
and reviewed by radiographers to ensure a certain tolerance 
Any problems encountered during the process (e.g. 
‘out-of-tolerance’ issue) referred to the physicist in 
charge 
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5.3 DOSIMETRY CHECK AND NON-UNIFORM BACKSCATTER 
5.3.1 Scatter effect from Varian EPID robotic arm 
Dosimetry Check provides a non-invasive technique suitable for in-vivo dosimetry 
verification and it also provides a reconstructed treatment-time patient dose distribution.   
However, the system inevitably comes with limitations, which means that there is not 
necessarily full agreement with calculations from the local TPS.  Some papers have indicated 
that a discrepancy in dose between TPS and Dosimetry Check, as a result of a difference in 
calculation algorithm, might raise concerns about the utility of the software as a highly accurate 
tool for treatment verification (Reilly et al., 2013, Fafi et al., 2013, Narayanasamy et al., 2015).  It 
is well known that the PB algorithm does not accurately correct for tissue heterogeneity in dose 
calculation with Dosimetry Check (Fafi et al., 2013, Reilly et al., 2013).  Furthermore, Dosimetry 
Check also has an issue with scattered dose from the Varian EPID support arm and to the best of 
current knowledge, work has not previously been done to correct the latter issue within the 
Dosimetry Check system.    
As discussed by Bawazeer et al. (2015), none of the available solutions for radiotherapy 
dose verification (Portal Dosimetry22, EPIDose23, Epiqa24, Dosimetry Check25, and EPIgray 
software26), corrects for backscatter from the Varian EPID  support arm.  This correction is the 
                                                        
22 Portal Dosimetry (Varian, Palo Alto, CA, USA) 
23 EPIdose (Sun Nuclear Corporation, Melbourne, Florida) 
24 Epiqa (EPIdos , Ivanka pri Dunaji, Bratislava, Slovakia) 
25 Dosimetry Check (Math Resolutions, LLC, Columbia) 
26 EPIgray (DOSIsoft S.A. (Cachan, France)) 
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main focus of the work detailed in this chapter.  The aim is to apply a key correction for non-
uniform backscatter from the EPID arm to improve the accuracy of patient specific dose 
verification using Dosimetry Check. 
5.3.2 Methods employed to overcome the scatter effect 
The impact of the backscatter from the EPID arm has been reported elsewhere (see 
Chapter 1, section 1.5).  It is known to cause up to 5% discrepancy between the delivered dose 
and calculated dose.  Some groups have investigated the addition of customised lead shielding 
beneath the imager panel to make the scattered radiation more uniformly distributed across 
the Varian aS500 EPID (Lung et al., 2004, Joseph and Jeffrey, 2005, Rowshanfarzad et al., 
2010b).  The newest Varian EPID panel (aS1200) incorporates this extra shielding in the design 
to help overcome the non-uniform scatter issue (Reilly, 2016a, Reilly, 2016b).  However, there 
are still many systems in use worldwide with earlier versions of the EPID panel and 
replacement with the newest version is not necessarily feasible due to the high cost of such 
equipment (~ £100K per unit).   
An alternative approach involving a convolution kernel model was developed by Greer 
et al. (2009) following research by Rowshanfarzad et al. (2010a).  This evaluated a ‘stand-alone’ 
EPID measurement involving the direct subtraction of a 1x1cm2 pencil beam kernel at a sample 
position on the EPID active area when the EPID arm was ‘on’ from the same measured kernel 
when the EPID arm was ‘off’.  It was claimed that this provided a more accurate incorporation of 
backscatter (using a backscatter pencil beam kernel) into their existing Pinnacle TPS EPID dose 
prediction model.   
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In this work, a series of rectangular field (2x20cm2, 3x20cm2, 5x20cm2 and 9x20cm2) 
images were acquired.  Multiple abutting strips (alphabetically labelled) for each field size were 
used; for example (i) 2x20cm2 has 11strips (A-K), (ii) 3x20cm2 has 7 strips (A-G), (iii) 5x20cm2 
has 5 strips (A-E) and (iv) 9x20cm2 has 3 strips (A-C).  These were sufficient to cover the EPID 
active area as illustrated in Figure 5.4.  Correction factors were derived for each case by 
mirroring half of the Y-axis beam profiles (on the EPID Couch side) about the central row to 
obtain symmetrical profiles (along the Y-axis of EPID imager) as shown in Figure 5.5 (a) and (b).  
The images were taken with variable rectangular field sizes in order to highlight the effect of 
backscatter from the EPID arm in the inferior region of the EPID and to record the variation of 
backscatter with the field sizes and location utilised. 
 As the aim the work is to provide a correction method to remove the effect of 
backscatter, the corrected matrix should necessarily display profiles that are symmetric or close 
to symmetric in the absence of backscatter in all clinical situations. 
These symmetric profiles were then interpolated across the whole aS1000 EPID area 
(comprising 768 x 1024 pixels) to obtain a correction matrix corresponding to each case.  An 
average correction matrix (denoted as the ‘M4’ matrix) was also constructed by taking the 
average of the 4 matrices obtained from all the field sizes (as detailed above).  In order to check 
the symmetry of the profiles after the application of M4, several equidistant point doses in the 
superior-inferior region of the EPID image were also set up in TPS on central strips through a 
water phantom for every field size (Figure 5.9 (a)). 
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Figure 5.4 - (a) An example of 2D colourmaps of a 5x20cm2 field case with multiple abutting strips (labelled with A-E) covering the active 
area of aS1000 EPID as shown in (b). 
(b) 
(a) 
EPID image of multiple abutting strips for 5x20cm2 field 
EPID 
Gantry side 
EPID  
Couch side 
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     (a)               (b) 
        Figure 5.5 - (a) An example of multiple strips from a 5x20cm
2 field (labelled with A-E) case where strips were mirrored by the central pixel row 
(black dotted line) of the EPID image to produce a symmetric profile on the Gantry side along Y axis.  Vertical  yellow dotted lines represent the 
points of interpolation taken to get a complete set of correction factors for the EPID.  
(b)  Examples of profiles for different field sizes cut through the in-line direction (yellow dotted lines from (a)) of EPID image; dashed lines-
corrected profiles on the gantry side (positive values of Y axis). 
Direction across Y axis 
EPID Gantry side EPID Couch side 
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Next, the utility of this M4 correction matrix was tested with a series of central square 
field sizes (2x2cm2, 3x3cm2, 5x5cm2, 10x10cm2 and 20x20cm2).  Firstly, to investigate the dose 
before applying the correction, the field images were fed into Dosimetry Check and analysed for 
the percentage difference between measured dose in Dosimetry Check and calculated TPS dose.  
Next, images in DICOM format were read as double precision array following a linear 
transformation (detailed in section 2.2.2.2) and then used to convert the corresponding image 
pixel to a useful measurement.  These steps were done with the aid of a Matlab script as 
illustrated in Figure 5.6.   
Next, rescaled values were obtained by multiplying these useful values with the M4 
matrix.  Subsequently, to be able to represent the newly generated rescaled values as image 
pixels in DICOM format, the linear transformation was again used to reproduce new pixel 
values that belong to the new image.  Finally, this corrected image was then written as a DICOM 
file with all metadata information retained from the original DICOM image structure. 
For a comparison to dose before correction, these corrected images for all fields were 
fed back into Dosimetry Check to investigate dose after correction being applied.  The analysis 
was done at point of interest (POI) in the inferior region of the EPID for each field size, for the 
corresponding Y axis profiles and for a gamma of 3%/3mm (Chapter 3) above a 20% threshold. 
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%%This script follows the generation of a new image after correction being 
%%applied 
 
figure; 
%Read and rescale the original image to obtain the meaningful data 
B03_RPO=(double(dicomread('RTIMAGE_6000X_B03_RPO-3_1_30_174527.dcm'))); 
inf_B03=dicominfo('RTIMAGE_6000X_B03_RPO-3_1_30_174527.dcm','dictionary','dicom-
dict-mod2.txt'); 
B03dat=inf_B03.RescaleIntercept+inf_B03.RescaleSlope.*B03_RPO; 
%%Apply M4 correction matrix to the rescaled values to obtain the 
%%corresponding pixel values 
WTI_B03_rponewdat=B03dat.*(M4); 
WTI_B03_rponewdat=uint16((WTI_B03_rponewdat-inf_B03.RescaleIntercept). 
/(inf_B03.RescaleSlope)); 
%%write new corrected image as DICOM file and display new corrected image 
dicomwrite(WTI_B03_rponewdat,'RI_B03_RPO_corrected.dcm',inf_B03,'CreateMode','copy'; 
 
 
 
 
In addition to the utility of the M4 correction matrix with the central square fields, the 
matrix was also validated and verified with an example of an IMRT Head-and-Neck case 
comprising a series of segmented fields.  All calibrations and irradiations were carried out at a 
dose-rate of 300 MUmin-1.  IMRT images (without any correction applied) were first evaluated 
and read in Dosimetry Check.   Subsequently, IMRT images corrected for backscatter (by means 
of multiplying images with M4 matrix using Matlab script) were obtained and read into 
Dosimetry Check.  The dose calculation grid in OMP TPS and Dosimetry Check was set to 0.3cm. 
In summary, the compatibility of the M4 matrix was tested with central square fields, 
off-axis square fields, rectangular fields and a clinical IMRT case.  The following comparisons 
between pre-correction and post-correction data were undertaken: 
Figure 5.6 – Example of coding in Matlab script for the implementation of the M4 correction matrix and 
generation of updated EPID images after correction. 
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A C E D 
i) point dose calculated by Dosimetry Check and TPS at the point of interest (POI) in the 
inferior region,  
ii) beam profiles along the in-line direction (refers to Y axis of an EPID image),  
iii) pass rate of gamma criterion (3%/3mm) on an IMRT Head-and-Neck case at both POI and 
dmax for the respective beams.   
An overview of the whole process is described in Figure 5.7. 
 
 
 
 
                      
 
 
 
 
 
Figure 5.7 - A process map describing the correction stages from the application of the correction matrix  
to the analysis of the results. 
Apply correction 
matrix to EPID raw 
images for IMRT 
beams 
Generate the 
corresponding 
corrected EPID images 
using Matlab script 
Create new DICOM 
images to and export 
to Dosimetry Check to 
read and analyse 
Compare pre and post 
correction dose 
generated by 
Dosimetry Check and 
dose computed by 
OMP TPS 
Assessment includes: 
i. point dose comparison of DC and TPS at point of 
interest (POI) in inferior area 
ii. investigation of the beam profiles along in-line 
(gantry-couch) direction  
iii. pass rate of gamma criterion (3%/3mm) on 
IMRT Head-and-Neck case for both POI and dmax 
respective beams 
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5.3.3 Results 
After a preliminary analysis of the efficacy of the correction method on the series of 
square fields, in summary it was found that using the M4 correction matrix gave good 
agreement, i.e. less than 2% difference between Dosimetry Check and TPS dose at POI.  Y axis 
profiles of the respective square fields showed improvement in the symmetry of line profiles 
using the M4 correction.  An average of 98% points passed gamma criterion of 3%/3mm for 
both coronal and sagittal planes of the POI after corrections compared to an average of 91% 
and 94% points for the coronal and sagittal planes respectively before correction.   
Table 5.1 illustrates the initial results obtained for the square fields.  It was found that 
the correction matrix is only beneficially applicable to fields of equivalent square less than 
approximately 12cm (e.g. 9x20cm2).  If the equivalent square field is greater than 12cm, there is 
no benefit in applying the correction (Figure 5.8 (a)).  Moreover, due to the limitation of the 
Dosimetry Check software, the scattered radiation is assumed to be constant across the EPID.  
For a very small 2x2cm2 field size (Figure 5.8 (b)), accurate calculation of POI dose is rather 
difficult and so there is no benefit in applying the correction. 
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Square 
fields 
(cm2) 
Dose Difference Y axis profiles (gantry-couch direction) 
Gamma criterion of 3%3mm above 
threshold 
Coronal (%) Sagittal (%) 
10x10 
before after Before after before after before after 
3.32% 1.19% 
  
85.50 96.8 90.00 96.87 
5x5 
before after Before after before after before after 
2.58% 1.44% 
  
94.80 100.00 100.00 100.00 
3x3 
before after Before after before after before after 
1.55% 1.31% 
  
91.21 95.81 91.13 95.84 
 2.48% 1.31%  Mean 90.50 97.54 93.71 97.57 
 0.89 0.13  Standard Deviation, SD 4.69 2.19 5.48 2.17 
Table 5.1- Results for several square field sizes tested with the M4 correction matrix.  Dose at the POI 
after correction shows better than 2% agreement with TPS, the profiles are more symmetrical and 
gamma is improved for coronal and sagittal planes. 
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(a)(i)                                                                                               (ii)       
 
 
            
(b)(i)                           (ii) 
 
 
 
 
20x20cm2 
Difference compared with TPS dose (%) 
Gamma (above 20%), 
3%3mm 
Point of Interest  Coronal Sagittal 
without correction 0.18 64.87 88.55 
with 'M4' correction -2.94 50.57 72.95 
2x2cm2 
Difference compared with TPS dose (%) 
Gamma (above 20%), 
3%3mm 
Isocentric point Coronal Sagittal 
without correction -2.00 86.96 86.11 
with 'M4' correction -2.22 85.51 82.82 
Figure 5.8 - (a) Profile for a 20x20cm2 field in the Y direction generated by Dosimetry Check 
illustrates that (i) The ‘humps’ before correction are overcorrected by the application of M4 (b) 
Profile for a 2x2cm2 field (i)before correction, (ii) after the application of the correction 
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The preliminary investigations also involved analysis of several equidistant sample 
points along the Y axis (superior-inferior) to assess the level of improvement of profile for all 
rectangular field sizes (2x20cm2, 3x20cm2, 5x20cm2 and 9x20cm2) after application of the M4 
correction matrix (Figure 5.9 (a) and (b)).  It was found that the percentage difference in 
asymmetry before and after correction was reduced by an average of 3% as tabulated in Table 
5.2 (a) and (b).       
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 Figure 5.9 – (a) Examples of 2D colourmaps of 3x20cm2 strips with equidistant points taken along the 
superior-inferior direction from the central row of the EPID respectively to certain off-axis distance from 
the central pixel after correction.  Yellow-3cm, red–6cm, green-9cm.  (b) Corresponding points illustrated on 
symmetric profiles with the same colour coded marks. 
 
(a) 
(b) 
Superior 
direction 
Inferior 
direction 
Superior 
direction 
Inferior 
direction 
Superior 
direction 
Inferior 
direction 
Superior 
area 
Inferior 
area 
Superior 
area 
Inferior 
area 
Superior 
area 
Inferior 
area 
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Table 5.2 - Examples of improvement in asymmetry before (β) and after (α) correction for 
equidistant points on several strips including some off-axis strips (a) 3x20cm2 field size (b) 5x20cm2 
field size 
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In addition, to show the effect on some off-axis fields after the application of backscatter 
correction, the correction matrix has also been verified with a series of square field ‘patches’ off-
axis (2x2cm2 - A, C, E and G, 3x3cm2 - A, C and E, and 5x5cm2 - A and C) inferior to the EPID 
(gantry side) (Figure 5.10).  This was done to confirm whether this correction could also be 
applied to off-axis square fields.   The corresponding results shown in Table 5.3. 
For point dose measurements made off-axis, after application of the correction there 
was good agreement with TPS calculations, the difference in general being less than 3% 
compared to the situation before correction, which showed differences of over 5%.   
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Figure 5.10 – Testing of correction matrix with series of off-axis square field patches (labelled with A, C, E and G) in the inferior area (positive values of Y axis 
of the EPID image) with 2x2cm2, 3x3cm2 and 5x5cm2 field sizes).  Cut through profiles show improvement after correction (blue solid lines) compared with 
before correction (red dotted lines). 
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Table 5.3 - Percentage point dose measurement difference between Oncentra MasterPlan TPS 
and Dosimetry Check showing agreement within 3% after application of correction and 
indicating that this method can be applied to off-axis fields. 
 
 
. 
 
 
  
 
 
Off-axis square field 
patches (distance from 
the centre) 
Point dose measurement difference (%) 
before after 
2x2cm2A (-1cm) 1.39 0.14 
2x2cm2C (-3cm) 1.90 1.17 
2x2cm2 E (-5cm) 3.42 1.90 
2x2cm2 G (-7cm) 2.97 1.97 
Off-axis square field 
patches (distance from the 
centre) 
Point dose measurement difference (%) 
before after 
5x5cm2A (-2.5cm) 4.68 2.28 
5x5cm2C (-7.5cm) 5.66 2.67 
Off-axis square field 
patches (distance from 
the centre) 
Point dose measurement difference (%) 
before after 
3x3cm2A (-1.5cm) 3.36 1.63 
3x3cm2C (-4.5cm) 6.56 2.89 
3x3cm2E (-7.5cm) 5.14 2.16 
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After correction was applied to the example IMRT Head-and-Neck case (Figure 5.11), 
the improvement in point dose measurement in the inferior region (gantry side) of the EPID 
image (where the non-uniform backscatter effect is predominant) was assessed in terms of 
percentage difference for all beams relative to the point doses given by the TPS.   It was found 
that the average dose difference was reduced by approximately 3% at the point of interest 
(POI) in the inferior region of the EPID image and at the dmax POI respectively (Table 5.4 (a)).  In 
summary, for transit dosimetry (dose delivered through a patient or phantom), the Dosimetry 
Check dose discrepancy relative to the TPS dose after correction was reduced by about 3% 
compared to the situation before correction.    
The sample points were positioned in the inferior region of the IMRT image at a 
distance from the central axis towards the gantry.  Points less than 1cm from the panel edge 
were excluded, since the correction factor was set to 1 (at ~1cm from the panel edge) to reduce 
uncertainties due to lateral scatter within the EPID.  Thus, the outcomes after correction are 
promising, with significant removal of the effect of non-uniform backscatter in complex 
treatment plans, such as the example IMRT Head-and-Neck plan with individual segmented 
beam profiles.   
For the coronal view, an average of 95% of points passed a gamma criterion of 
5%/3mm (at both POI and dmax POI) with the backscatter correction applied, compared to an 
average of 90% and 85% (at POI and dmax of POI respectively) before correction.  The gamma 
5%/3mm criterion was chosen for the case of transit dosimetry (in-vivo) following the 
recommendation in ICRU report 83, which set a pass rate of 85% (ICRU, 2010).  Similarly, in the 
sagittal view, 93% of points passed the gamma criterion at POI whereas 97% passed at dmax 
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POI, compared to an average of 85% and 95% (at POI and dmax POI respectively) before the 
application of the correction (Table 5.5 (a) and (b)).  
Note that the all POIs placed in the inferior part of the IMRT beams are in the following 
order and coordinates;  
i.e. BeamN = (x, y, z), where N is the beam number,  
x = x-axis coordinate in cm,  
y = y-axis coordinate in cm,  
z = z-axis coordinate in cm. 
1) Beam01 = (-4.6, -6.3, 0.0) 
2) Beam02 = (2.2, -5.1, 0.0) 
3) Beam03 = (-2.8, -5.7, 0.0) 
4) Beam04 = (-2.9, -3.1, 0.0) 
5) Beam05 = (-4.3, -3.1, 0.0) 
6) Beam06 = (1.4, -4.1, 0.0) 
7) Beam07 = (-1.6, -3.4, 0.0) 
8) Beam08 = (-2.2, -3.4, 0.0) 
9) Beam09 = (3.6, -3.9, 0.0) 
10) Beam10 = (3.0, -5.5, 0.0) 
11) Beam11 = (-3.3, -7.1, 0.0) 
12) Beam12 = (5.4, -6.0, 0.0) 
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Table 5.4 - Percentage reduction in point dose for Dosimetry Check relative to the TPS after the 
application of the correction for (a) transit in-vivo dosimetry (b) pre-treatment dosimetry
(a) 
 
Beams 
(transit) 
Dose difference for Dosimetry Check relative to TPS (%) 
POI dmax POI 
before after 
Percentage 
changed 
before after 
Percentage 
change 
B01 3.38 1.19 -2.19 3.73 1.32 -2.41 
B02 5.22 1.80 -3.42 6.20 2.76 -3.85 
B03 0.68 -0.39 -1.07 4.35 1.07 -3.28 
B04 7.70 4.51 -3.09 7.34 2.65 -3.39 
B05 8.07 4.93 -3.14 7.54 4.25 -3.29 
B06 2.20 -0.81 -3.01 2.30 -0.91 -3.21 
B07 7.39 4.38 -3.01 8.39 5.05 -3.34 
B08 8.82 5.83 -2.69 9.07 6.09 -2.98 
B09 2.14 1.09 -1.05 3.89 0.45 -3.44 
B10 5.44 1.86 -3.58 5.92 2.34 -3.58 
B11 3.77 0.87 -2.90 6.69 3.75 -2.94 
B12 3.08 -0.11 -3.19 3.96 0.94 -3.02 
Average 4.79 2.10 -2.70 5.78 2.48 -3.30 
σ 2.64 2.26 0.84 2.12 2.04 0.54 
(b) 
Beams 
(pre-
treatment) 
Dose difference for Dosimetry Check relative to TPS (%) 
POI dmax POI 
before after 
Percentage 
changed 
before after 
Percentage 
change 
B01 4.29 1.22 -3.07 4.3 1.20 -3.10 
B02 4.32 1.09 3.23 6.92 2.53 -4.39 
B03 3.88 0.76 -3.12 6.22 2.09 -4.13 
B04 5.07 1.20 3.87 6.27 2.21 -4.06 
B05 4.42 1.29 -3.13 5.09 2.03 -3.06 
B06 3.48 0.97 -2.51 1.84 -0.57 -2.41 
B07 3.57 1.06 -2.51 4.84 1.91 -2.93 
B08 4.21 1.69 -2.52 5.36 2.92 -2.44 
B09 3.40 0.45 -2.95 4.88 2.11 -2.77 
B10 4.34 0.56 -3.78 5.42 1.63 -3.79 
B11 5.06 2.37 -2.69 7.07 3.97 -3.10 
B12 4.37 1.44 -2.93 5.88 2.86 -3.02 
Average 4.20 1.18 -3.03 5.34 2.07 -3.27 
σ 0.55 0.52 0.45 1.39 1.09 0.66 
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Similar results were obtained for the case of pre-treatment delivery, which involves 
verification of dose delivered without a patient or phantom.  Point dose difference relative to 
the TPS was reduced by about 3% compared to the situation before correction (Table 5.4 (b)).  
A 95% pass rate for routine Gamma Index criteria of 3%/3mm for doses above a 20% 
threshold was used for the pre-treatment situation and the results are shown Table 5.6 (a) and 
(b).    
After correction, 98% and 95% points passed the gamma criterion for POI and dmax 
respectively in the coronal view, compared to 87% and 82% before correction.  The Gamma 
Index pass rate also improved in the sagittal view from 83% and 92% before correction to 96% 
and 97% for POI and dmax POI respectively after correction.  Simple point dose comparison is 
currently implemented clinically in Velindre Cancer Centre for conformal treatment, and the 
correction method described above improves in-line beam profiles in the inferior region (away 
from the gantry) for a sample IMRT plan.  For example, in Figure 5.12 (a), a beam profile (B03-
RPO) which cuts through the Y-axis at EPID imager level, demonstrated a significant 
improvement after the application of the correction.  Agreement between Dosimetry Check and 
TPS profiles to within 1% at the inferior end after correction also can be seen in Figure 5.12 (b).  
In addition, improvement was also achieved when correction was applied to a small segmented 
beam profile in the inferior region as shown in Figure 5.13.    
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 Figure 5.11 - Representation of a beam profile B03 cut along Y axis of the EPID image before and after the application 
of the correction for an IMRT Head-and-Neck case. 
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(b) 
Figure 5.12 - (a) Change in image intensity at the EPID level before and after correction. (b) Profile comparison between TPS dose and EPID 
reconstructed dose (in vivo) given by the Dosimetry Check software.  Black solid line is TPS dose, red dotted line is DC dose before correction and 
blue dotted line is Dosimetry Check dose after correction.  Agreement between black solid line and blue dotted line is within 1% after correction 
from more than 3% before correction.    
 
(a) 
(b) 
Y axis from the centre (cm) 
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Figure 5.13 - Examples of beams involving small segmented fields in the inferior region (the cut 
through black dashed line varies for each beam).  The cut-through profiles show improvement after 
application of the correction. 
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Table 5.5 - Percentage of points passing gamma criterion of 5%/3mm above a threshold of 20% 
for transit dosimetry at (a) POI and (b) dmax POI. 
(a) 
 
Gamma 
pass rate 
(%) for 
all 
beams-
(cut 
through 
POI of 
the 
beam) 
Beams 
Gamma 5%/3mm (coronal) Gamma 5%/3mm (sagittal) 
Before correction 
(%) 
After 
correction 
(%) 
Before correction 
(%) 
After correction 
(%) 
B01 98.36 100.00 96.05 99.76 
B02 89.47 95.52 81.87 90.02 
B03 91.83 97.42 85.60 91.80 
B04 94.74 99.95 94.24 99.00 
B05 87.10 94.46 69.16 86.35 
B06 97.62 98.23 91.98 96.91 
B07 85.69 92.78 76.90 92.44 
B08 72.68 85.22 61.07 75.34 
B09 89.09 98.47 96.97 97.85 
B10 86.74 94.22 86.98 92.94 
B11 89.11 91.68 99.92 100.00 
B12 93.29 96.88 83.35 95.23 
Average 89.64 95.40 85.34 93.14 
σ 6.76 4.18 11.78 7.01 
(b) 
 
Gamma 
pass rate 
(%) for 
all 
beams-
(cut 
through 
dmax POI 
of the 
beam) 
Beams 
Gamma 5%/3mm (coronal) Gamma 5%/3mm (sagittal) 
Before 
correction 
(%) 
After correction 
(%) 
Before 
correction (%) 
After correction 
(%) 
B01 95.52 98.87 98.76 100.00 
B02 77.22 92.02 85.73 91.10 
B03 90.10 97.70 95.75 97.55 
B04 88.62 99.68 96.70 99.06 
B05 82.18 91.14 86.24 95.05 
B06 97.01 98.93 96.42 98.94 
B07 82.61 92.17 89.37 98.74 
B08 66.38 78.70 81.32 91.18 
B09 86.52 98.15 98.65 96.02 
B10 79.28 90.83 95.32 96.61 
B11 82.75 99.50 99.94 100.00 
B12 91.62 96.17 97.73 98.76 
Average 84.98 94.49 93.49 97.00 
σ 8.52 6.05 6.17 3.11 
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Table 5.6 - Percentage of points passing gamma criterion of 3%/3mm above a threshold of 20% 
for pre-treatment dosimetry at (a) POI and (b) dmax  POI
(a) 
 
Gamma 
pass rate 
(%) for 
all 
beams-
(cut 
through 
POI of 
the 
beam) 
Beams 
Gamma 3%/3mm (coronal) Gamma 3%/3mm (sagittal) 
Before 
correction (%) 
After 
correction (%) 
Before correction 
(%) 
After 
correction (%) 
B01 85.51 96.47 88.34 97.85 
B02 74.25 95.22 60.89 92.94 
B03 73.83 99.00 70.88 100.00 
B04 84.55 96.93 84.10 95.23 
B05 83.93 96.18 77.87 93.99 
B06 98.88 99.91 93.35 96.13 
B07 94.70 99.92 85.50 98.66 
B08 82.93 99.64 80.49 96.57 
B09 89.18 100.00 94.21 95.63 
B10 89.29 98.94 81.40 93.46 
B11 95.80 99.51 97.76 99.91 
B12 95.44 100.00 85.00 96.27 
Average 87.36 98.48 83.32 96.39 
σ 8.13 1.76 10.27 2.35 
(b) 
 
Gamma 
pass rate 
(%) for 
all 
beams-
(cut 
through 
dmax POI 
of the 
beam) 
Beams 
Gamma 3%/3mm (coronal) Gamma 3%/3mm (sagittal) 
Before 
correction (%) 
After 
correction (%) 
Before correction 
(%) 
After 
correction (%) 
B01 85.66 97.98 77.31 92.67 
B02 77.15 94.00 88.90 93.32 
B03 81.67 96.67 90.72 93.89 
B04 84.34 95.98 91.15 98.34 
B05 68.49 88.85 86.48 97.77 
B06 88.85 97.55 97.91 98.97 
B07 87.03 99.04 92.85 99.07 
B08 75.69 92.99 92.97 98.82 
B09 85.28 97.57 98.89 99.03 
B10 70.81 90.10 90.86 97.53 
B11 83.70 88.58 99.85 99.91 
B12 91.62 99.85 95.38 98.73 
Average 81.69 94.93 91.94 97.34 
σ 7.18 3.97 6.15 2.53 
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A further component of the analysis involved the Gamma index pass rates calculated by 
the Dosimetry Check software for two simple example arbitrary volumes27, V1 and V2 (Figure 
5.14).  For V1, 92% and 97% of points passed the 5%/3mm gamma criterion after correction, 
compared to 84% and 93% before correction for POI and dmax respectively in transit dosimetry 
verification.  For pre-treatment dosimetry, the Gamma Volume pass rate results for V1 
improved to 94% and 98% after correction, compared to 85% and 93% before correction for 
POI and dmax respectively (Table 5.7).  The pass rates for V2 also improved to a maximum of 
98% for pre-treatment dosimetry and 97% for transit dosimetry from minima of 82% before 
correction for both cases (Table 5.8). 
 
 
 
 
  
 
 
                                                        
27 Arbitrary volume– refers to a random choice rather than any particular reason for defining a volume 
V1 
V2 
Figure 5.14 - Outlines of arbitrary volumes V1 (red) and V2 
(blue) within a water phantom to demonstrate the difference in 
Gamma Volume results calculated by Dosimetry Check. 
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Table 5.7 - Gamma index pass rates results for volume V1 delineated within a water phantom. 
 
 
 
 
 
Gamma      
results for V1 
Beams 
Transit dosimetry, cumulative Gamma index Pre-treatment dosimetry, cumulative Gamma index 
Before correction (%) After correction (%) Before correction (%) After correction (%) 
POI dmax POI dmax POI dmax POI dmax 
B01 92.57 98.30 98.76 99.98 71.70 81.19 85.87 90.76 
B02 82.94 88.25 92.98 94.34 71.32 87.12 86.26 92.54 
B03 86.27 96.39 94.20 98.41 93.53 93.39 95.99 96.74 
B04 90.38 97.19 98.98 99.78 95.42 98.36 98.97 99.27 
B05 81.17 91.24 90.12 96.45 75.80 88.97 90.43 97.41 
B06 94.84 97.47 96.81 97.99 93.97 99.24 96.57 99.88 
B07 81.88 90.16 90.32 94.09 91.68 96.54 99.27 99.63 
B08 67.21 82.18 79.76 92.44 78.79 89.76 96.34 99.10 
B09 85.59 94.38 94.02 98.78 83.80 93.21 95.86 99.86 
B10 78.53 92.81 88.14 95.47 80.84 92.72 90.96 98.62 
B11 84.26 91.02 87.12 93.50 89.60 95.04 94.96 98.65 
B12 87.73 95.34 93.73 97.04 90.44 96.72 98.21 99.82 
Average 84.45 92.89 92.08 96.52 84.74 92.69 94.14 97.69 
σ 7.24 4.66 5.44 2.54 8.85 5.21 4.66 3.01 
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Table 5.8 - Gamma index results for volume V2 delineated within a water phantom. 
 
 
 
 
 
 
 
 
Gamma 
results for V2 
Beams 
Transit dosimetry, cumulative Gamma index Pre-treatment dosimetry, cumulative Gamma index 
Before correction (%) After correction (%) Before correction (%) After correction (%) 
POI dmax POI dmax POI dmax POI dmax 
B01 91.35 98.79 98.45 99.99 71.08 78.97 83.36 89.90 
B02 82.05 87.75 94.09 95.85 70.44 84.18 86.48 95.98 
B03 82.89 96.02 92.75 99.33 90.98 90.80 98.67 99.67 
B04 88.13 95.70 98.97 99.90 93.86 97.59 97.68 99.99 
B05 76.12 88.07 86.58 95.13 72.12 85.16 89.13 96.11 
B06 95.56 98.26 98.20 99.03 91.48 97.90 94.80 98.96 
B07 80.36 89.36 89.79 94.37 89.71 95.04 98.99 99.49 
B08 62.89 78.74 76.31 90.59 73.92 86.51 93.49 98.16 
B09 83.43 93.11 92.66 98.76 78.15 91.31 91.57 99.47 
B10 74.63 91.16 85.97 95.50 75.55 88.57 87.25 95.98 
B11 82.99 89.72 86.26 92.57 87.27 93.01 93.30 97.20 
B12 84.87 94.63 92.12 96.96 85.19 95.44 95.26 99.53 
Average 82.11 91.78 91.01 96.50 81.65 90.37 92.50 97.54 
σ 8.41 5.60 6.55 3.04 8.56 5.61 4.84 2.74 
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5.3.4 Discussion  
Ensuring accurate patient dose calculation is a crucial aspect of the radiotherapy 
process.  In the context of this work, the removal (or at least the reduction) of the effect of non-
uniform backscatter due to the EPID arm and its auxiliary components underneath the panel, is 
clearly an important observation.  The introduction of a novel correction method to overcome 
the issue when using Dosimetry Check software leads to more accurate treatment verification 
with advanced radiotherapy techniques.  A visible “hump” on the left of the Y-axis profile 
measured by Dosimetry Check which resulted from the backscatter was reported during 
commissioning due to the effect of calibration of the acquired image with flood field image.  
Both of these images experienced backscatter from the arm which cancelled each other out at 
one side and left the other side with a pronounced “hump”.  On the other hand, the “rounding” 
of the profile with increasing field size (Figure 5.2), has been confirmed by Math ResolutionsTM 
to be due to a limitation of the software, in which scattered radiation is assumed to be constant 
across the EPID.   
  One of the major aims of this study was to correct for asymmetries in the EPID raw 
image. The backscatter correction matrix developed by this work has the potential to improve 
significantly both pre-treatment and in-vivo transit dose verification using Dosimetry Check.  It 
is evident that improvement in gamma pass rates demonstrates that this method would be 
suitable for application in advancing the accuracy of the existing Dosimetry Check verification 
tool, especially in a clinical setting where only point dose measurement is being routinely 
applied at the moment.   
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Prior to implementing this correction clinically, further steps would be required in the 
form of setting up and commissioning procedures for all the relevant linacs, to ensure the 
general effectiveness of the correction.  In addition, the correction is also intended to apply to 
VMAT treatment techniques; the segmented IMRT technique described in this chapter is just 
one of a number of advanced radiotherapy delivery methods employed at Velindre Cancer 
Centre.   The potential application of this correction matrix approach to VMAT is discussed in 
the next chapter on a ‘proof of principle’ basis.   
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Chapter 6  
APPLICATION OF DOSIMETRY CHECK TO THE VERIFICATION OF 
VOLUMETRIC MODULATED ARC THERAPY 
6.1 NEW VERIFICATION TOOL FOR VMAT TREATMENT VERIFICATION 
The theme of this chapter is an extension of the investigations of Dosimetry Check 
undertaken for IMRT described in Chapter 5.  In this chapter, Dosimetry Check is investigated as 
a tool for VMAT treatment verification (discussed in Chapter 1 and 2).  VMAT is one of the most 
advanced treatment techniques currently available, with shorter treatment delivery times than 
segmented IMRT for example.  VMAT delivery verification using cine images28 for both pre-
treatment and transit dosimetry is discussed and relevant results presented.  When fully 
commissioned for VMAT verification, it is anticipated that Dosimetry Check will provide a key 
facility in the Velindre Cancer Centre. 
6.1.1 EPID challenges with VMAT delivery technique 
In recent years, newer treatment techniques, such as VMAT, have necessitated more 
sophisticated planning and delivery facilities and achieved higher dose conformity with shorter 
                                                        
28 Cine images – Continuous sequence of images taken in a full VMAT delivery cycle.  
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treatment times compared to IMRT.  With VMAT, the linear accelerator rotates around the 
patient during treatment and simultaneously, the machine’s MLC continuously reshapes and 
changes the intensity of the radiation beam as it does so.  The arc of rotation is associated with 
variable gantry speed and dose-rate.  VMAT has received extensive attention recently, and it has 
moved from research into clinical implementation to treat most of the cancers for which 
radiotherapy is used  (Mijnheer et al., 2013b, Greer, 2013, Aristophanous et al., 2016).  
However, VMAT is an even more complex delivery technique than IMRT (Chapter 2).  In order 
to create a satisfactory dose plan with a single arc, it is necessary to optimise the field shapes 
and beam intensities for a large number of gantry angles (so-called control points).  Where 
necessary Velindre Cancer Centre plans with 2 arcs – one with clockwise and the other with 
anticlockwise rotation.  Hence, a robust system of patient dosimetric QA using EPIDs, needs to 
be available for the verification.    
Most dosimetric investigations to date have been undertaken using the aSi-EPID imager 
in an ‘integrating’ acquisition mode (as for IMRT), where the image signal is integrated over an 
entire irradiation to produce a single dosimetric image (Van Esch et al., 2004, Iori et al., 2010, 
Blake et al., 2014, Bawazeer et al., 2017).  More recent studies have examined the potential 
dosimetric characteristics of the aSi-EPID imager operated in ‘cine’ acquisition mode 
(continuous mode) where the image signal is read out electronically throughout an irradiation 
to produce a series of images (Ansbacher et al., 2010, Rowshanfarzad et al., 2011, 2012, 
Bawazeer et al., 2016).   
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Similar to the ‘traditional’ EPID-based IMRT QA, VMAT QA techniques verify MLC 
positions as a function of delivered MU directly or by a pixel intensity-based comparison.  It has 
been noted that EPID-based pre-treatment QA for VMAT could be more effective if the gantry 
angle were also routinely recorded, along with the MLC position and delivered MU.  However, 
by design, the gantry angle rotation cannot be detected by the EPID due to its fixed position on 
the gantry.  A straightforward solution is to apply a recorded gantry angle provided by the linac 
vendor in the DICOM header of the cine images.  However, this has been shown to give poor 
precision for some vendors’ systems (Ansbacher et al., 2010).  The application of an 
inclinometer has also been utilised to verify gantry angle rotation.  It has the advantage of 
providing an independent measurement of gantry angle, although it requires synchronisation 
with the linac and/or the acquired EPID images, and the inclinometer also may be subjected to 
time delay and inertia29 effects from the moving gantry (Barnes et al., 2016).  A previous review 
has discussed some difficulties associated with using an EPID for VMAT pre-treatment 
verification (Greer, 2013).   
First, there is the effect of EPID ‘sagging’ or ‘flexing’ during an arc. The detector panel 
experiences gravitational sagging as a function of gantry angle and this causes displacement of 
the acquired frames from each other, with subsequent blurring of the integrated dose.   
Rowshanfarzad et al. (2012) used a marker placed at the isocentre and corrected for marker 
                                                        
29 Inertia - is the resistance of any physical object to any change in its state of motion (including a change in 
direction). In other words, it is the tendency of objects to keep moving in a straight line at constant linear velocity. 
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displacement during the arc rotation.  They found that the reproducibility of the sag pattern in a 
Varian EPID system is linac dependent.  The sag was more pronounced in the in-line direction 
(approximately 1mm) compared to the crossline direction (approximately 0.5mm).  The use of 
an additional holding device to clamp the mounting accessory, which held the EPID in position 
during rotation, was a physical approach developed by Iori et al. (2010).  They have been able to 
limit the EPID sag to less than 1mm with this device.  However, no investigation of EPID sagging 
was done during the course of this work due to time limitations, hence this must be taken into 
account when verifying VMAT for clinical use. 
A second issue cited by Greer (2013) is the use of cine mode image acquisition, which is 
required in order to verify dose as a function of gantry angle for VMAT delivery.  In cine mode, 
individual images are acquired continuously during treatment delivery.  In contrast, the 
standard ‘integrated’ image aggregates the dose information from all gantry angles into one 
image and therefore cannot fully validate the delivery.  Several studies have examined cine-
mode image acquisition using different EPID systems.  For example, Piermattei et al. (2009) 
investigated cine-mode for the IAS2 system30 with a 0.6Hz acquisition rate and found that 
imaging with a low dose-rate (of 100MUmin-1) gave good signal stability of ±1% over a period 
of 3 months.  McCurdy and Greer (2009) compared the use of cine-mode of the IAS3 system31 
(7.5Hz) against integrated mode in terms of dosimetric performance.  This approach allowed 
discarded frames due to loss of beam signal or beam-off to be identified and, at the same time, 
                                                        
30 IAS2 – an Image Acquisition Software for Varian aSi500 Electronic Portal Imaging Device (EPID) 
31 IAS3 – an Image Acquisition Software for Varian aSi1000 Electronic Portal Imaging Device (EPID) 
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reduced memory overflow problems during delivery.  However, it has been demonstrated 
(Ansbacher et al., 2010, McCowan et al., 2017) that gantry angle uncertainty during rotation 
related to images acquired with a Varian aSi-EPID typically exceeds the tolerance of 1° specified 
by the AAPM TG142 report (Klein et al., 2009). 
Thirdly,  banding artefacts may be evident due to different rows of the imager being  
read out at slightly different times (Woodruff and Greer, 2013).  Each row can therefore 
integrate different numbers of beam pulses depending on when the pulses are dropped.  As the 
rows also are read out in batches, with each batch read out simultaneously, the solution to 
minimising the artefacts is to average the multiple frames for the angles subtended by each of 
the cine-mode EPID images.  However, known drawbacks are the effect of dose averaging on 
those frames with degradation of the portal image quality (Hansjoerg et al., 2010) and a 
decrease in the EPID’s angular resolution (McCowan and McCurdy, 2016).  
6.1.2 Rationale of Dosimetry Check use in VMAT verification  
A number of studies have reported the use of Dosimetry Check software for the pre-
treatment verification of VMAT techniques (Pinkerton et al., 2010, Greer, 2013, Villaggi, 2016, 
McCowan et al., 2017), but there are very few reports on ‘in vivo’ dosimetry (Reilly, 2016b, 
Villaggi, 2016).  Therefore, in this work, the investigation of the use of Dosimetry Check in 
VMAT is intended to complement and improve on the current pre-treatment verification 
methods available. 
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6.1.3 Methods 
The fact that the acquisition modes (continuous or integrated) work in a different way 
for portal dosimetry verification, necessarily means that the Dosimetry Check software also 
works differently for each case.  Hence, certain preliminary investigations must be carried out 
beforehand on (a) the Dosimetry Check dose response with different dose rates and different 
Monitor Units (MUs) in continuous mode, (b) the difference (if any) between continuous and 
integrated images and (c) the appropriate calibration method to be used in Dosimetry Check for 
the cine images.  The EPID was set at 150cm SDD for all measurements unless stated otherwise.      
6.1.3.1 Dosimetry Check dose response against Monitor Units and dose rate in 
continuous mode 
The linearity of Dosimetry Check dose response against MU delivered at different dose 
rates in continuous mode was investigated by acquiring images with a static field size of 
10x10cm2.  A series of images were obtained with totals of 25, 50, 100, 300 and 600 MU 
delivered.  All calibrations and irradiations were carried out at dose rates of 300MUmin-1 and 
600MUmin-1.   
Images were exported to Dosimetry Check to obtain the measured dose calculated by 
the software.  This test did not look at dose difference or agreement between OMP and 
Dosimetry Check as generated in the Dosimetry Check report.  The focus was on the linearity of 
dose response by Dosimetry Check when conditions were varied in terms of dose rate and the 
total MU delivered.   
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Further analysis was made to evaluate the number of acquired cine images in each MU 
delivery with different dose rates and a constant frame acquisition rate (~9.57 frames per 
second).  In order to calculate ‘missing’ images, the number of acquired images in each MU 
delivery was subtracted from the expected number of acquired images.  The expected number 
of acquired images was directly taken from the linac service mode with the same delivery set 
up, on the assumption that service mode operation gave the true number of images in 
proportion to total MU increment.    
6.1.3.2 Reproducibility of dose in continuous mode 
Dose reproducibility in continuous mode was also investigated.  Several evaluation 
points were set on a 10x10cm2 field size, the dose calculated using OMP TPS (Figure 6.1) and 
exported to Dosimetry Check.  Multiple images were acquired in continuous mode for 300 and 
600MU exposures at dose rates of 300MUmin-1 and 600MUmin-1.  The difference between dose 
measured by Dosimetry Check at 600MUmin-1 relative to dose measured by Dosimetry Check 
at 300MUmin-1 was calculated for each delivery. 
 
 
 
 
Figure 6.1 - Points of interest (POI)  set up 
in TPS on a 10x10cm2 square field size to 
calculate the difference in dose measured 
by Dosimetry Check for software 
reproducibility 
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6.1.3.2.1 Results and discussion 
Figure 6.2 shows Dosimetry Check dose response per MU delivered for the two dose 
rates (300MUmin-1 and 600MUmin-1).  Linearity is clearly seen for integrated mode across the 
total MU delivered with dose difference between the dose rates consistently close to zero.  
However, for continuous mode (Figure 6.3), about 4% dose difference was observed at higher 
monitor units (600MU) between the two dose rates with a slight under-response of 
0.04cGy/MU at 600MU for a delivery rate of 600MUmin-1 compared to 300MUmin-1.  This is 
probably due to loss of Relative Monitor Unit (RMU) fluence signal resulting from some missing 
images or frames during irradiation in continuous mode at higher MU (~600MU in this case).  
However, at lower MUs (˂50MU in this case), the dose difference was around 1.7%.  This was 
due to the fact that fewer frames were acquired in total by the IAS3 image acquisition system.  
Hence, a slight dose discrepancy was observed as the result of the frame averaging effect.  
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Figure 6.2 – Dosimetry Check dose response per MU delivered as a function of total MU and dose 
rate for the integrated acquisition mode showing nearly 0% difference between the two dose 
rates.  Dose responses were normalised at 100MU. 
Figure 6.3 - Dosimetry Check dose response per MU delivered as a function of total MU and dose 
rate for the continuous acquisition mode.  Dose responses were normalised at 100MU. 
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The corresponding number of images generated in continuous acquisition as a function 
of MU delivery is shown in Table 6.1 for 300MUmin-1 and 600MUmin-1 dose rates.   For values of 
total MU up to 300, it was found that the number of EPID images recorded in each delivery was 
the same as the number of expected cine images in that delivery.  However, the number of 
acquired images decreased at 600MU delivery, with 1 image and 7 images being lost during 
acquisition for 300 and 600MUmin-1 dose rates respectively.  This effect was believed (and 
subsequently confirmed by the vendor) to be the result of a loss of communication in 
continuous mode.  This is because, in continuous mode, the image can be captured between 
beam pulses.  Therefore, if pulses are dropped with dynamic treatments, the IAS3 loses its 
synchronisation with the linac pulses.  In this case, the acquisition can drop images before 
capturing images again.  Physically, the array of TFTs which are embedded inside the aS1000 
EPID panel were rapidly integrating the resulting charges and caused the desynchronization.  
 
Table 6.1 - Number of acquired images in continuous mode irradiation for a clinical setting 
compared to number of images acquired in service mode (true value). 
Total MU 
delivered 
300MU/min (images) 600MU/min (images) 
Service Mode Clinical Mode Service Mode Clinical Mode 
25 4 4 4 4 
50 16 16 9 9 
100 33 33 18 18 
300 100 100 56 56 
600 200 199 112 105 
Difference 200-199 = 1 image 112-105 = 7 images  
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Results of the comparison of point doses assessed by Dosimetry Check in continuous 
mode acquisition for 600MU delivered are tabulated in Table 6.2 (a).   On average, there was a 
dose difference of 4.7% obtained between the two delivery dose rates.  The results confirmed 
the non-linearity of dose response at higher MU (600MU) (Figure 6.3).  However, for delivery at 
lower MU (300MU), good agreement was obtained with an average dose difference between 
the dose rates less than 2% (Table 6.2 (b)).   
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Table 6.2 - (a) Comparison between dose generated by Dosimetry Check for 600MU 10x10cm2 
square field in continuous mode. (b) Comparison between dose generated by Dosimetry Check 
for 300MU 10x10cm2 square fiend in continuous mode. 
 
 
(a) No. of 
points 
Coordinates in field 
Dosimetry Check dose (cGy) Percentage 
difference (%) 300MU/min 600MU/min 
1 (0, 0, 0) 501.1 478.7 -4.68 
2 (0, 2, 0) 499.8 476.9 -4.80 
3 (2, 0, 0) 502.4 480.0 -4.67 
4 (0, -2, 0) 505.9 483.1 -4.72 
5 (-2, 0, 0) 502.2 479.9 -4.65 
6 (-3.8, 3.8, 0) 475.1 453.5 -4.76 
7 (3.8, 3.8, 0) 475.9 454.2 -4.78 
8 (3.8, -3.8, 0) 487.1 464.9 -4.78 
9 (-3.8, -3.8, 0) 485.1 463.1 -4.75 
 (a) Average -4.73 
σ 0.06 
(b) No. of 
points 
Coordinates in field 
Dosimetry Check dose (cGy) Percentage 
difference (%) 300MU/min 600MU/min 
1 (0, 0, 0) 243.4 246.6 1.30 
2 (0, 2, 0) 250.6 246.0 1.87 
3 (2, 0, 0) 244.2 247.3 1.25 
4 (0, -2, 0) 245.6 248.6 1.21 
5 (-2, 0, 0) 244.2 247.3 1.25 
6 (-3.8, 3.8, 0) 232.0 235.0 1.28 
7 (3.8, 3.8, 0) 232.5 235.4 1.23 
8 (3.8, -3.8, 0) 237.5 240.2 1.12 
9 (-3.8, -3.8, 0) 236.6 239.4 1.17 
(b) Average 1.33 
σ 0.22 
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6.1.3.3 Calibration method used in Dosimetry Check for continuous mode verification 
From the results obtained so far, it is apparent that there is the possibility of some loss of 
accuracy when images are acquired for extended periods (~1min) or when dose is delivered at 
a high rate.   With Dosimetry Check, a single image produced by an integrated mode is 
calibrated or normalised by using a standard 10x10cm2 field size image acquired in the same 
mode.  Similarly, calibration of continuous images (e.g. for VMAT fields) with Dosimetry Check 
should be performed with set of standard 10x10cm2 images acquired in continuous mode.  As 
explained previously, there is the possibility of inaccuracy in continuous mode due to loss of 
image frames.  When this happens, there will be some discrepancy between the dose measured 
by Dosimetry Check and that calculated by the OMP TPS.     
Hence, a calibration method was developed and used for the rest of the VMAT 
verification investigations with Dosimetry Check.  To begin with, images were acquired for a 
10x10cm2 field delivered through a 360° arc from -180° to 180° with a total 600MU at each 
dose rate (300MUmin-1 and 600MUmin-1), and the images exported to Dosimetry Check.  Then, 
the cine images from the arc were calibrated with a set of images for a 10x10cm2 field at 100MU 
also acquired in continuous mode.  For comparison, the same arc was also calibrated against 
images for a 10x10cm2 field at 100MU acquired in integrated mode.  Doses recorded by 
Dosimetry Check were investigated for any significant discrepancies.  When a discrepancy or 
image loss was identified, a correction step in the calibration method (3rd calibration option 
available in Dosimetry Check) was needed for continuous acquisition.  Determination of the 
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correction factor involved calibrating the continuous arc images with the result of integration of 
these arc images into a single image.      
6.1.3.3.1 Results and discussion 
As illustrated in Figure 6.4, VMAT dose using continuous images acquired with 600MU 
gave good agreement between Dosimetry Check and OMP when calibrated with cine images at 
300MUmin-1.  Differences at the isocentre were less than 1%.  On the other hand, Figure 6.5 
shows that the percentage difference between OMP and Dosimetry Check dose was somewhat 
greater, especially at the isocentre (~1.5%) for 600MU at 600MUmin-1.  This was due to some 
loss of radiation dose through missing frames or images.  However, when a single integrated 
image of an arc was used as the calibration file, the agreement was excellent (less than 1% at 
isocentre) as illustrated in Figure 6.6.  Dosimetry Check incorporates the correction using this 
method by computing a single correction factor, let us say k, as a ratio for all pixels (which have 
≧0.25 of the maximum pixel value in each image), of the measured dose and the value from the 
sum of continuous images at the same pixel location.  The average k ratio is then computed and 
taken as the correction factor. 
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Cross-line profile for 10x10cm2 arc 
calibrated with cine images at 300MUmin-1 
In-line profile for 10x10cm2 arc  
calibrated with cine images at 300MUmin-1 
Figure 6.4 - Dose profiles in the cross-line and in-line directions for a 10x10cm2 arc irradiated at 600MU and calibrated at 300MUmin-1 with their 
respective percentage difference (within ±1% in high dose region). 
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Cross-line profile for 10x10cm2 arc 
calibrated with cine images at 600MUmin-1 
In-line profile for 10x10cm2 arc  
calibrated with cine images at 600MUmin-1 
Figure 6.5 - Dose profiles in the cross-line and in-line directions for a 10x10cm2 arc irradiated at 600MU and calibrated at 600MUmin-1 with their 
respective percentage difference (mostly greater than 1.5% in high dose region). 
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Cross-line profiles for 10x10cm2 arc 
calibrated with single arc integration 
In-line profiles for 10x10cm2 arc calibrated 
with single arc integration 
Figure 6.6 - Dose profiles in the cross-line and in-line directions for a 10x10cm2 arc irradiated at 600MU and calibrated with a  single image produced 
by the integration of an arc with their respective percentage difference (within 2% in most high dose region). 
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6.1.4 Introduction of backscatter correction into the VMAT technique 
This section describes the incorporation of correction for backscatter from the linac 
robotic arm in VMAT using the key correction matrix that was investigated in Chapter 5.   
6.1.4.1 Methods 
The implementation of the correction matrix (M4) with VMAT treatment delivery was 
investigated with some basic arcs (with field sizes 10x10cm2 and 5x18cm2) and a water 
phantom.  Images for both arcs were acquired for 300MU at a dose rate of 300MUmin-1.  The 
same approach as before (Matlab script) was used to obtain a set of corrected cine images by 
multiplying the M4 matrix with the set of raw EPID cine images (see example in Figure 6.7).  
Data were analysed for beam profiles across the Y-axis before and after the application of the 
correction.  
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dirName=cd('Y:DICOM images\VMAT images\Arc10x10_600MU'); 
dcmfiles=dir (fullfile(dirName, '*dcm')); 
resultsVMAT='Y:\DICOM images\VMAT images|Arc10x10_600MU\RI_VMAT10x10_correction'; 
 
 
for j=1: length(dcmfiles); 
 files=dcmfiles(j).name; 
 fulldcm=fullfile(dirName,files); 
 
 %Read and rescale the original image to obtain the meaningful data 
 Arc1=(double(dicomread(fulldcm))); 
 Inf1=dicominfo (fulldcm, 'dictionary','dicom-dict-mod2.txt'); 
 Arc1dat=inf1.RescaleIntercept+inf1.RescaleSlope. *Arc1; 
 
 %%Apply M4 correction matrix to the rescaled values to obtain the 
 %%corresponding pixel values 
 Arc1newdat=Arc1dat.*(M4); 
 Arc1newat=uint16((Arc1newdat-inf1.RescaleIntercept). /(inf1.RescaleSlope)); 
 
 %%write new corrected image as DICOM file and display new corrected image 
 dicomwrite (Arc1newdat,[resultsVMAT,num2str(j), '.dcm'],inf1, 'CreateMode',  
'copy'); 
end; 
 
 
6.1.4.1 Results and discussion 
Figure 6.8 and Figure 6.9 show that the backscatter effect was reduced by an average of 
approximately 2% from the centre of Y-axis to the left edge of the beam for both the 10x10cm2 
arc and the 5x18cm2 arc.  With the correction applied, agreement between TPS and Dosimetry 
Check dose improved from an average of ≈2.4% to ≈0.4% for the 10x10cm2 arc and from an 
average of ≈2.5% to ≈0.1% for the 5x18cm2 arc.  This demonstrates that the method of 
correction is appropriate to be used for VMAT verification using Dosimetry Check.  
Figure 6.7 - Example of coding in Matlab script used to obtain a set of corrected cine images. 
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 Figure 6.8 - Y-axis profiles of TPS (black bold line) and Dosimetry Check dose before and after correction for a 10x10cm2 arc.  The Dosimetry 
Check dose profile before correction (red dotted line) shows the effect of backscatter from the linac arm on the left.  The backscatter is improved  
after correction (yellow bold line).  The profiles are normalised to the TPS central axis dose.  A zoomed plot is also shown for clarity. 
 
In-line profiles for a 10x10cm2 arc 
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Figure 6.9 - Y-axis profiles of TPS (black bold line) and Dosimetry Check dose before and after correction for a 5x18cm2 arc.  The Dosimetry Check 
dose profile before correction (red dotted line) shows the effect of backscatter from the linac arm on the left.  The backscatter is improved  after 
correction (yellow bold line).  The profiles are normalised to the TPS central axis dose.  A zoomed plot is also shown for clarity. 
 
In-line profiles for a 5x18cm2 arc 
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6.2 CASE STUDY: VMAT HEAD-AND-NECK PRE-TREATMENT 
VERIFICATION 
The feasibility of applying the backscatter correction matrix method to a clinical VMAT 
plan was investigated with the expectation of improving the accuracy of verification using 
Dosimetry Check.  Gamma evaluation was also included in the analysis of this plan.   
6.2.1 Methods 
The same Head-and-Neck plan as discussed previously (in Chapter 5) was used after re-
planning for VMAT delivery with the same linac (LA5).  The plan was re-optimised and 
calculated in OMP with a cylindrical Head-and-Neck phantom (Figure 6.10 (a)).  The calculation 
dose grid was set to be 0.3cm (similar to the situation previously discussed in Chapter 5).  Due 
to the fact that the cylindrical Head-and-Neck phantom was too short to cover the whole VMAT 
beam from the superior to inferior edge (Figure 6.10 (b)), the phantom was shifted 4cm 
inferiorly.  This resulted in the plan extending further than the phantom superiorly, but the 
inferior region of the beam was the area of interest in order to highlight the effect of the 
backscatter from the arm.  A ROI (Figure 6.10 (c)) was introduced within the external volume of 
the phantom with a 3cm margin inwards, for the evaluation of a Gamma Volume Histogram 
during dose reconstruction using Dosimetry Check.  The plan was acquired pre-treatment on 
LA5 and delivered at a 600MUmin-1 dose rate.   
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Figure 6.10 – (a) Head and Neck phantom 
used as the RT structure image in the 
optimisation process through OMP TPS.  
(b) Head and Neck phantom with the 
VMAT irradiation beams optimised and 
calculated in OMP TPS.  
(c) ROI (red volume) created internally 
within the phantom for the evaluation of 
GVH during dose reconstruction using 
Dosimetry Check. 
 
(b) 
(a) 
(c) 
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Finally, several aspects of the data obtained before correction and after correction were 
evaluated: 
i) improvement of the beam profiles along in-line direction (Gantry-Couch),  
ii) pass rate of the gamma criteria 3%/5mm and 3%3mm 
iii) pass rate of Gamma Volume (Chapter 5) for the VMAT pre-treatment plan 
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6.2.2 Results and discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11 - (a) Profiles cut through the Y axis of a coronal plane of the VMAT plan (yellow dotted line)  
before (red dotted line) and after correction (blue bold line) for backscatter compared with TPS calculated 
dose (black bold line).  (b) Correction produced an average reduction of 3% in dose difference (taken from 
the central axis 0cm to-10cm) relative to TPS dose.   
 
 
 
(a) 
(b) 
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Figure 6.11 shows that the average percentage difference relative to TPS dose improved 
from 4.2% before correction to around 1.7% after correction.  The relative differences were 
taken from the centre point to the end of inferior part of the coronal view plane (negative values 
on the X-axis of the graph).   
It was found that 95% and 97% of points passed gamma criterion of 3%/5mm for 
coronal and sagittal planes respectively.  Points passing a 3%/3mm criterion were also 
evaluated and showed a good result with a pass rate of more than 85% for both planes.  Gamma 
Volume for the ROI outlined within the Head-and-Neck phantom also improved from 73% 
before correction to 87% after correction for a 3%/3mm gamma criterion, and from 89% to 
95% for a 3%/5mm criterion.  Detailed results are tabulated in Table 6.3 and a pictorial 
description is presented in Figure 6.12.  
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Table 6.3 - Tabulated result of points passing the gamma criterion and GVH for a pre-treatment 
VMAT Head-and-Neck pre-treatment plan. 
 
VMAT Head-and-
Neck  
pre-treatment 
plane 
Gamma criteria pass rate (%) 
3%/3mm 3%/5mm 
Before After Before After 
Coronal 69.63 86.47 84.33 95.25 
Sagittal 75.16 90.02 87.84 97.12 
Average 72.40 88.36 86.09 96.19 
Gamma criteria 
Cumulative Gamma Volume index on ROI  
Before correction After correction 
3%3mm 72.62% 87.03% 
3% 5mm 88.52% 95.42% 
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Figure 6.12 - Graphic presentation of 2D gamma evaluation of the pre-treatment Head-and-Neck VMAT plan for a 3%/5mm criterion.  Red area shows 
regions with failing gamma reconstructed and reported in Dosimetry Check. 
VMAT 
plane 
Before correction, 3%/5mm After correction, 3%/5mm 
Coronal  
  
84.33% 
  
95.25% 
Sagittal 
  
87.84% 
  
97.12% 
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The investigation of this correction method demonstrated that it can be applied 
effectively to improve the accuracy of treatment verification.  Although the experiment only 
verified the case using a water equivalent phantom, it should be a good basis for further 
investigations leading to patient specific QA verification.   
Since VMAT is a very complex type of treatment technique, it is crucial that plans are 
verified before treatment delivery.  Evidently, the improvement in gamma and Gamma Volume 
pass rate shows that this method would be suitable for enhancement of the existing Dosimetry 
Check verification system.  
6.3 ADAPTIVE ARM BACKSCATTER SOLUTION (ADABS) FOR 
TREATMENT VERIFICATION USING DOSIMETRY CHECK 
From the series of experiments that were carried out to investigate the arm backscatter 
effect, with extended application to IMRT and VMAT treatment techniques, it was apparent that 
the correction matrix method was suitable for use to reduce systematic uncertainties due to the 
effect and promised improved accuracy for the verification system.   
To accommodate the future application of this approach and to facilitate its systematic 
use in the clinic, a more convenient way of routinely applying the correction matrix was 
explored.  This was required because a large number of plans must be verified, and these must 
be accurate as possible.  Hence, to avoid having to utilise a long Matlab-based scripted system 
external to Dosimetry Check to generate a corrected image for each plan, an alternative solution 
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step was developed for future use.  For simplicity, this is called Adaptive Arm Backscatter 
Solution (AdABS) from this point onwards.    
In Dosimetry Check, there is an option (“Correct with Flood View”), which may be 
used if there is a need to shift the EPID from the central axis for a field measurement.  Under 
these circumstances, a correction for a flood view must be applied to obtain the correct shape of 
the beam profile relative to the flattening filter.  However, there is no EPID shifting involved in 
this work, and so this facility offers an easy-to-apply method to correct for backscatter from the 
linac arm that may be applied to all images at the same time.    
However, if a measurement requires the EPID to be shifted to an off-set panel position, 
the same correction should not be applied when “Correct with Flood View” is required at the 
same time.  Therefore, a new correction needs to be formulated for the off-set panel position 
first, then both corrections (flood field and backscatter from the arm) could be combined.  The 
steps involved in the process of converting EPID images to Relative Monitor Units are shown in 
Figures 6.13 - 6.15 as screen-shots of the Dosimetry Check software. 
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Figure 6.13 – Step 1: Plan and beam selection. 
 
The plan was exported to Dosimetry Check from the 
TPS.  Pixels from the EPID raw image are assigned 
to give the same value as that at the centre of a 
standard (10x10cm2) calibration file (a). 
 
(1) 
 
(1) 
 
(1) 
 
(1) 
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Figure 6.14 - Step 2: Application of correction. 
Image of the backscatter correction matrix uploaded in DICOM 
format (b) into the Dosimetry Check calibration pane using the 
“Correct with Flood View” facility. 
 
(2) 
 
(2) 
 
(2) 
 
(2) 
(b) 
 
(2) 
 
(2) 
 
(2) 
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Figure 6.15 - Step 3: Calibration of the 
image. 
Set of calibration images (c) selected to 
centre all field images (VMAT cine images 
in this example) with known signal and 
Monitor Units.   Ratio of MU/signal 
generated as a calibration constant which 
is automatically applied to all field images. 
 
(3) 
 
(3) 
 
(b) 
 
(2) 
 
(2) 
 
(2) 
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To assess the effectiveness of the application of AdABS, dose profiles for static fields of 
10x10cm2 and 5x20cm2 dimension were investigated.  TPS profiles were compared with (i) DC 
profiles without backscatter correction, (ii) Dosimetry Check profiles corrected with the Matlab 
script and (iii) Dosimetry Check profiles corrected with AdABS.  A large field (20x20cm2) was 
also examined in the same way.   
6.3.1 Results and discussion  
Figure 6.16 shows cross-line beam plots for the two simple fields (10x10cm2 and 
5x20cm2).  For both fields, profiles corrected for backscatter with the scripted method and with 
AdABS showed excellent agreement, with percentage differences of less than 1.5% compared to 
TPS suggesting that AdABS is a feasible correction method that may be applied in the clinic for 
more accurate treatment verification. 
However, the test with a larger 20x20cm2 field (Figure 6.17), showed an adjustment to 
the profiles which seems non-beneficial with both the methods applied, although their 
difference remained at nearly 1%.  This demonstrates that the generic correction matrix retains 
some field dependence as stated previously in Chapter 5.  In addition, this effect was not known 
but yet believed to be part of backscatter related to the cross-line direction, therefore indicating 
the limitation in the method employed in this work to produce a universal correction for all field 
sizes.  However, in practice, for most of the clinical applications involving advanced 
radiotherapy, fields much smaller than 20x20cm2 are involved. 
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One of the reasons for the difference between script-based correction images and the 
AdABS application is the effect of acquiring the image matrix from the flat image in DICOM 
format using Matlab.  The flat image is derived from the normalisation of a flood image with 
itself.  The easiest way to mitigate this effect is to apply the matrix correction directly to the 
flood field image rather than the flat image, so that the profile shape can be retained.  
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Comparison of in-line profiles for 10x10cm2 field Comparison of in-line profiles for 5x20cm2 field 
Figure 6.16 - Comparison of in-line profiles for simple fields (10x10cm2 and 5x20cm2) before correction (red dashed line), after correction with Matlab script 
(green bold line) and AdABS (yellow bold line).  Black dashed line is the TPS dose.  Good agreement is achieved with dose difference of less than 1.5% for both 
methods (purple dotted line). 
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Figure 6.17 – In-line profiles for a 20x20cm2 field size before correction (red dashed line) and after 
backscatter correction.  The plots show the adjustment to the part of the field (left side of the plots) 
using the correction matrix for the Matlab script and AdABS methods.  However, both methods were 
in agreement with nearly 1% in percentage dose difference  (purple dotted line).  
 
Comparison of in-line profiles for 20x20cm2 field 
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While Dosimetry Check is already proven to be a versatile tool, this work suggests that it 
could benefit from the implementation of backscatter correction to improve its performance as 
regards to verification accuracy.  The correction matrix provides a ready solution that may be 
incorporated into Dosimetry Check for any linac with the same EPID panel.  Thus, this may 
prove to be an essential tool for RT verification with Dosimetry Check, which may be 
introduced into clinical practice in the near future.     
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Chapter 7  
CONCLUSION 
7.1 CONCLUSION 
This work focused on the development of techniques for the verification of advanced 
radiotherapy (specifically IMRT & VMAT) by portal dosimetry. The following main goals were 
achieved. 
1. A correction method for backscatter from the EPID arm (Varian aS1000) was 
developed (Chapter 5). The solution was derived from quantification of the non-
uniform backscatter reaching the EPID from the arm and resulted in fully symmetrical 
profiles being generated across the EPID. The technique proved effective and efficient 
in correcting for the effect of non-uniform backscatter on equivalent square field sizes 
≦12cm.  This solution has also been shown to be suitable for application to clinical 
IMRT, an example of which involved a Head-and-Neck case. Incorporating the 
solution improved the Gamma Index pass rate analysed for the example case from 
82% to 98% for pre-treatment dosimetry (evaluated at 3%/3mm) and from 85% to 
97% for the transit dosimetry (evaluated at 5%/3mm). 
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2. The work in Chapter 5 also demonstrated that the Dosimetry Check portal dosimetry 
software system performed well as a verification tool, in terms of accuracy in the 
verification of IMRT treatments, with an average 3% reduction in linac arm 
backscatter effect as a result of the correction method. 
3. This work showed that by applying the backscatter correction method in Dosimetry 
Check, wider treatment plan verification could be employed clinically (at Velindre 
Cancer Centre and elsewhere) using beam profile measurement and 2D dose image 
comparison, in addition to the point dose measurements employed at the moment. 
4. A ‘proof-of-concept’ of this novel correction method was shown to give benefit to pre-
treatment VMAT verification techniques (Chapter 6). This solution also improved the 
agreement between TPS calculated dose and Dosimetry Check measured dose by 
applying the correction matrix to a continuous set of images obtained during the arc 
treatment. Average pre-treatment Gamma Index pass rates (for 3%/5mm criterion) 
improved from 86% to 96% after correction, with an average of 3% reduction in 
percentage dose difference inferior to the in-line direction between Dosimetry Check 
and TPS on coronal beam profiles of the arc. 
5. The application of AdABS as an efficient method (Chapter 6) of utilising the correction 
to verify treatment plans within the Dosimetry Check system was investigated.  This 
technique provided a feasible way of applying the correction within Dosimetry Check 
without the need to generate corrected images using external software (Matlab) 
scripts for every plan. Ultimately, this will benefit clinical advanced radiotherapy 
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treatment plan verification by providing a ready solution that will help with (a) 
minimising storage requirements for saving images and (b) implementing a quick and 
efficient workflow in Dosimetry Check. 
7.2 FUTURE WORK  
One of the areas for further development of the work described in this thesis relates to 
the fact that the matrix-based correction method retains some degree of field-size dependence. 
However, as the main aim of this work was to enhance clinical treatment verification for 
IMRT/VMAT, the segmented field sizes involved are generally sufficiently small to benefit from 
the method. In the future, a suitable correction matrix should be investigated for larger field 
sizes (˃12 cm equivalent square field).  Indeed, it is possible that a library of suitable correction 
matrices could be generated to apply for a fuller range of field sizes. 
Furthermore, this work concentrated on Head-and-Neck planning and it could be 
extended to the verification of IMRT of other tumour sites.  Increasing the number of clinical 
cases would provide more evidence for confidence in the usefulness of the correction strategy.  
With further work, it is possible that the correction matrix approach could be applied effectively 
to a wide range of clinical treatments. 
Although the correction matrix method was shown to be effective in the verification of 
VMAT treatment delivery with the Dosimetry Check software, in this work only pre-treatment 
verification was investigated and discussed.  Although the results are very encouraging, further 
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work is necessary to fully verify the application of the correction to the transit dosimetry of 
clinical VMAT.  
Further work on the AdABS approach to arc delivery is also necessary so ensure that the 
technique piloted here fully utilises Dosimetry Check to calculate dose within the patient and 
provides an accurate dose comparison with the TPS. 
Finally, the use of the Varian aS1000 EPID employed in this work should not imply that 
the procedure applies only to this device.  Any panel that is similarly affected by non-uniform 
backscatter should be able to benefit from this correction method to improve the performance 
and accuracy of in-vivo dosimetry. 
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